References

• Abilify (aripiprazole) [product monograph]. Saint-Laurent, QC, Canada, Otsuka Canada Pharmaceutical, November 2017
• Abilify (aripiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, August 2019
• Abilify Maintena (aripiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, March 2018. Available at: www.otsuka-us.com/media/static/Abilify-M-PI.pdf. Accessed January 20, 2019.
• Abilify Mycite (aripiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, November 2017
• Acevedo A, Garnick DW, Dunigan R, et al: Performance measures and racial/ethnic disparities in the treatment of substance use disorders. J Stud Alcohol Drugs 76(1):57–67, 2015
• Achtyes E, Simmons A, Skabeev A, et al: Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry 18(1):292, 2018 30223804
• ACOG Committee on Practice Bulletins—Obstetrics: ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111(4):1001–1020, 2008 18378767
• Acosta FJ, Hernández JL, Pereira J, et al: Medication adherence in schizophrenia. World J Psychiatry 2(5):74–82, 2012 24175171
• Addington D, McKenzie E, Smith H, et al: Conformance to evidence-based treatment recommendations in schizophrenia treatment services. Can J Psychiatry 57(5):317–323, 2012 22546064
• Addington DE, Norman R, Bond GR, et al: Development and testing of the First-Episode Psychosis Services Fidelity Scale. Psychiatr Serv 67(9):1023–1025, 2016 27032665
• Addington D, Abidi S, Garcia-Ortega I, et al: Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. Can J Psychiatry 62(9):594–603, 2017a
• Addington D, Anderson E, Kelly M, et al: Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders. Can J Psychiatry 62(9):662–672, 2017b
• Addington D, Birchwood M, Jones P, et al: Fidelity scales and performance measures to support implementation and quality assurance for first episode psychosis services. Early Interv Psychiatry 12(6):1235–1242, 2018 29882236
• Addington J, Addington D, Abidi S, et al: Canadian treatment guidelines for individuals at clinical high risk of psychosis. Can J Psychiatry 62(9):656–661, 2017 28730848
• Adelufosi AO, Abayomi O, Ojo TM: Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev April 13(4):CD010501, 2015 25866243
• Agency for Healthcare Research and Quality: Methods guide for effectiveness and comparative effectiveness reviews (AHRQ Publ No 10(14)-EHC063-EF). Rockville, MD, Agency for Healthcare Research and Quality, January 2014. Available at: www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. Accessed February 15, 2017.
• Agerwala SM, McCance-Katz EF: Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs 44(4):307–317, 2012 23210379
• Aggarwal NK, Lewis-Fernández R: An introduction to the Cultural Formulation Interview. Focus 13(4):426–431, 2015
• Ahalt C, Williams B: Reforming solitary-confinement policy: heeding a presidential call to action. N Engl J Med 374(18):1704–1706, 2016 27144846
• Ahalt C, Haney C, Rios S, et al: Reducing the use and impact of solitary confinement in corrections. Int J Prison Health 13(1):41–48, 2017 28299967
• Ahmed S, Khan AM, Mekala HM, et al: Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: a comparative meta-analysis. Heliyon 3(11):e00429, 2017 29264404
• Ajmal A, Joffe H, Nachtigall LB: Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 55(1):29–36, 2014 24140188
• Alabed S, Latifeh Y, Mohammad HA, Bergman H: Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev Apr 17 4(4):CD000203, 2018 29663328
• Alastal Y, Hasan S, Chowdhury MA, et al: Hypertriglyceridemia-induced pancreatitis in psychiatric patients: a case report and review of literature. Am J Ther 23(3):e947–949, 2016 24987947
• Alban RF, Nuño M, Ko A, et al: Weaker gun state laws are associated with higher rates of suicide secondary to firearms. J Surg Res 221:135–142, 2018 29229119
• Alberti KG, Eckel RH, Grundy SM, et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645, 2009 19805654
• Aleman A, Enriquez-Geppert S, Knegtering H, Dlabac-de Lange JJ: Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: meta-analysis of controlled trials. Neurosci Biobehav Rev 89:111–118, 2018 29471017
• Ali SA, Mathur N, Malhotra AK, Braga RJ: Electroconvulsive therapy and schizophrenia: a systematic review. Mol Neuropsychiatry 5(2):75–83, 2019 31192220
• Alldredge BK: Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 53(5 suppl 2):S68–S75, 1999 10496236
• Allen JG, Frueh BC, Ellis TE, et al: Integrating outcomes assessment and research into clinical care in inpatient adult psychiatric treatment. Bull Menninger Clin 73(4):259–295, 2009
• Almerie MQ, Al Marhi MO, Jawoosh M, et al: Social skills programmes for schizophrenia. Cochrane Database Syst Rev Jun 9(6):CD009006, 2015 26059249
• Al-Rousan T, Rubenstein L, Sieleni B, et al: Inside the nation’s largest mental health institution: a prevalence study in a state prison system. BMC Public Health 17(1):342, 2017 28427371
• Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, et al: Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22(7):547–562, 2008 18547125
• Alvir JM, Lieberman JA, Safferman AZ, et al: Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329(3):162–167, 1993 8515788
• Amantadine hydrochloride capsules [prescribing information]. High Point, NC, Banner Life Sciences, December 2015
• Amantadine hydrochloride oral solution [prescribing information]. Farmville, NC, CMP Pharma, January 2015
• Amantadine hydrochloride tablets [prescribing information]. Yardley, PA, Vensun Pharmaceuticals, January 2019
• American Academy of Pediatrics and the American College of Obstetricians and Gynecologists: Guidelines for Perinatal Care, 8th Edition. Elk Grove Village, IL, American Academy of Pediatrics; Washington, DC, American College of Obstetricians and Gynecologists, 2017
• American College of Correctional Physicians: Restricted housing of mentally ill inmates. Marion, MA, American College of Correctional Physicians, 2013. Available at: http://accpmed.org/restricted_housing_of_ mentally.php. Accessed September 22, 2019.
• American College of Obstetricians and Gynecologists: ACOG Committee Opinion No. 736: Optimizing postpartum care. Obstet Gynecol 131(5):e140–e150, 2018 29683911
• American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice; Breastfeeding Expert Work Group: Committee Opinion No. 658: Optimizing support for breastfeeding as part of obstetric practice. Obstet Gynecol 127(2):e86–92, 2016 26942393
• American Diabetes Association: 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 41 (suppl 1):S13–S27, 2018
• American Geriatrics Society Expert Panel on Person-Centered Care: Person-centered care: a definition and essential elements. J Am Geriatr Soc 64(1):15–18, 2016 26626262
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
• American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd Edition. Arlington, VA, American Psychiatric Publishing, 2004
• American Psychiatric Association: Position statement on treatment of substance use disorders in the criminal justice system. Arlington, VA, American Psychiatric Association, 2007. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2007-Substance-Abuse-Criminal-Justice.pdf. Accessed September 22, 2019.
• American Psychiatric Association: Guideline Watch: Practice Guideline for the Treatment of Patients With Schizophrenia. Arlington, VA, American Psychiatric Publishing, 2009a
• American Psychiatric Association: Position statement on atypical antipsychotic medications. Arlington, VA, American Psychiatric Association, 2009b. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2009-Atypical-Antipsychotics.pdf. Accessed September 22, 2019.
• American Psychiatric Association: Outpatient services for the mentally ill involved in the criminal justice system. Arlington, VA, American Psychiatric Association, 2009c. Available at: www.psychiatry.org/File%20 Library/Psychiatrists/Directories/Library-and-Archive/task-force-reports/tfr2009_outpatient.pdf. Accessed September 27, 2019.
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013a
• American Psychiatric Association: Clinician-rated dimensions of psychosis symptom severity, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013b, pp 743–744. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM5_ Clinician-Rated-Dimensions-of-Psychosis-Symptom-Severity.pdf. Accessed November 10, 2019.
• American Psychiatric Association: DSM-5 self-rated level 1 cross-cutting symptom measure—adult, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013c, pp 738–739. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM5_Level-1-Measure-Adult.pdf. Accessed November 10, 2019.
• American Psychiatric Association: WHODAS 2.0 (World Health Organization Disability Assessment Schedule 2.0): 36-item version, self-administered, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013d, pp 747–748. Available at: www.psychiatry.org/ psychiatrists/practice/dsm/educational-resources/assessment-measures. Accessed November 10, 2019.
• American Psychiatric Association: Glossary of technical terms, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013e, pp 817–831
• American Psychiatric Association: The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry, 2013 Edition. Arlington, VA, American Psychiatric Association, 2013f. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Practice/Ethics/principles-medical-ethics.pdf. Accessed November 18, 2018.
• American Psychiatric Association: Resource document on involuntary outpatient commitment and related programs of assisted outpatient treatment. Arlington, VA, American Psychiatric Association, 2015. Available at: www.psychiatry.org/psychiatrists/search-directories-databases/library-and-archive/resource-documents. Accessed October 2, 2019.
• American Psychiatric Association: Practice Guidelines for the Psychiatric Evaluation of Adults, 3rd Edition. Arlington, VA, American Psychiatric Association Publishing, 2016a
• American Psychiatric Association: Psychiatric Services in Correctional Facilities, 3rd Edition. Arlington, VA, American Psychiatric Association Publishing, 2016b
• American Psychiatric Association: Position statement on segregation of prisoners with mental illness. Arlington, VA, American Psychiatric Association, 2017. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2012-Prisoners-Segregation.pdf. Accessed September 22, 2019.
• American Psychiatric Association: Position statement on solitary confinement (restricted housing) of juveniles. Washington, DC, American Psychiatric Association, 2018. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2018-Solitary- Confinement-Restricted-Housing-of-Juveniles.pdf. Accessed October 3, 2019.
• American Public Health Association: Solitary confinement as a public health issue. Washington, DC, American Public Health Association, 2013. Available at: www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/14/13/30/solitary-confinement-as-a-public-health-issue. Accessed on September 22, 2019.
• Ananth J, Sangani H, Noonan JP: Amantadine in drug-induced extrapyramidal signs: a comparative study. Int J Clin Pharmacol Biopharm 11(4):323–326, 1975 239908
• Anderson GD, Chan LN: Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 55(11):1353–1368, 2016
• Anderson KE, Stamler D, Davis MD, et al: Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4(8):595–604, 2017 28668671
• Anderson KK, Norman R, MacDougall A, et al: Effectiveness of early psychosis intervention: comparison of service users and nonusers in population-based health administrative data. Am J Psychiatry 175(5):443–452, 2018 29495897
• Andorn A, Graham J, Csernansky J, et al: Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the phase 3 program. J Clin Psychopharmacol 39(5):428–433, 2019 31343440
• Andreasen NC: Scale for the Assessment of Negative Symptoms. Iowa City, University of Iowa, 1984a
• Andreasen NC: Scale for the Assessment of Positive Symptoms. Iowa City, University of Iowa, 1984b
• Andrews JC, Schünemann HJ, Oxman AD, et al: GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol 66(7):726–735, 2013 23570745
• Anestis MD, Houtsma C: The association between gun ownership and statewide overall suicide rates. Suicide Life Threat Behav 48(2):204–217, 2018 28294383
• Ang MS, Abdul Rashid NA, Lam M, et al: The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol 37(6):651–656, 2017 29016375
• Angell B, Matthews E, Barrenger S, et al: Engagement processes in model programs for community reentry from prison for people with serious mental illness. Int J Law Psychiatry 37(5):490–500, 2014 24650496
• Angus S, Sugars J, Boltezar R, et al: A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 17(2):88–91, 1997 10950469
• Appelbaum PS: Clinical practice: assessment of patients’ competence to consent to treatment. N Engl J Med 357(18):1834–1840, 2007
• Appelbaum PS, Le Melle S: Techniques used by assertive community treatment (ACT) teams to encourage adherence: patient and staff perceptions. Community Ment Health J 44(6):459–464, 2008 18516679
• Arana GW, Goff DC, Baldessarini RJ, Keepers GA: Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 145(8):993–996, 1988 2899403
• Aripiprazole orally disintegrating tablets [prescribing information]. Bridgewater, NJ, Alembic Pharmaceuticals, November 2018
• Aripiprazole solution [prescribing information]. Weston, FL, Apotex, November 2016
• Aristada (aripiprazole lauroxil) [prescribing information]. Waltham, MA, Alkermes, August 2019
• Aristada Initio (aripiprazole lauroxil) [prescribing information]. Waltham, MA, Alkermes, August 2019
• Ascher-Svanum H, Zhu B, Faries D, et al: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 67(7):1114–1123, 2006 16889456
• Aune D, Sen A, Norat T, et al: Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 133(7):639–649, 2016 26746176
• Austedo (deutetrabenazine) tablets [prescribing information]. North Wales, PA, Teva Pharmaceuticals USA, July 2019
• Aytemir K, Maarouf N, Gallagher MM, et al: Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 22(9):1397–1401, 1999 10527023
• Bachmann CJ, Aagaard L, Bernardo M, et al: International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 136(1):37–51, 2017 28502099
• Bai YM, Ting Chen T, Chen JY, et al: Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 68(8):1218–1225, 2007 17854246
• Baillargeon J, Binswanger IA, Penn JV, et al: Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 166(1):103–109, 2009a 19047321
• Baillargeon J, Penn JV, Thomas CR, et al: Psychiatric disorders and suicide in the nation’s largest state prison system. J Am Acad Psychiatry Law 37(2):188–193, 2009b 19535556
• Baillargeon J, Hoge SK, Penn JV: Addressing the challenge of community reentry among released inmates with serious mental illness. Am J Community Psychol 46(3–4):361–375, 2010 20865315
• Bak M, Fransen A, Janssen J, et al: Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 9(4):e94112, 2014 24763306
• Balon R, Berchou R: Hematologic side effects of psychotropic drugs. Psychosomatics 27(2):119–120, 125–127, 1986 2869545
• Balshem H, Helfand M, Schünemann HJ, et al: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406, 2011 21208779
• Barber S, Olotu U, Corsi M, Cipriani A: Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev (3):CD006324, 2017 28333365
• Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25(5):567–620, 2011
• Barnhill JW: The psychiatric interview and mental status examination, in The American Psychiatric Publishing Textbook of Psychiatry, 6th Edition. Edited by Hales RE, Yudofsky SC, Roberts LW. Arlington, VA, American Psychiatric Association, 2014, pp 3–30
• Barrowclough C, Tarrier N, Lewis S, et al: Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. Br J Psychiatry 174:505–511, 1999 10616628
• Bartels SJ, Pratt SI, Mueser KT, et al: Long-term outcomes of a randomized trial of integrated skills training and preventive healthcare for older adults with serious mental illness. Am J Geriatr Psychiatry 22(11):1251–1261, 2014 23954039
• Bartels SJ, Pratt SI, Aschbrenner KA, et al: Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 172(4):344–352, 2015 25827032
• Bassett AS, Chow EW: 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol Psychiatry 46(7):882–891, 1999 10509171
• Bassett AS, Lowther C, Merico D, et al: International 22q11.2DS Brain and Behavior Consortium: rare genome-wide copy number variation and expression of schizophrenia in 22q11.2 deletion syndrome. Am J Psychiatry 174(11):1054–1063, 2017 28750581
• Bäuml J, Froböse T, Kraemer S, et al: Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families. Schizophr Bull 32 (suppl 1):S1–S9, 2006 16920788
• Bebbington P, Jakobowitz S, McKenzie N, et al: Assessing needs for psychiatric treatment in prisoners, 1: prevalence of disorder. Soc Psychiatry Psychiatr Epidemiol 52(2):221–229, 2017 27878322
• Bech P, Austin SF, Timmerby N, et al: A clinimetric analysis of a BPRS-6 scale for schizophrenia severity. Acta Neuropsychiatr 30(4):187–191, 2018 29409548
• Beck AT, Rector NA: Cognitive approaches to schizophrenia: theory and therapy. Annu Rev Clin Psychol 1:577–606, 2005 17716100
• Beck AT, Rector NA, Stolar N, Grant P: Schizophrenia: Cognitive Theory, Research, and Therapy. New York, Guilford, 2009, p 418
• Beck Institute: CBT for schizophrenia. Bala Cynwyd, PA, Beck Institute, 2019. Available at: https://beckinstitute.org/workshop/cbt-for-schizophrenia. Accessed May 6, 2020.
• Becker DR, Drake RE: A Working Life for People With Severe Mental Illness. New York, Oxford University Press, 2003
• Bellack AS, Goldberg RW: VA Psychosocial Rehabilitation Training Program: social skills training for serious mental illness. Baltimore, MD, MIRECC VISN 5, 2019. Available at: www.mirecc.va.gov/visn5/training/sst/sst_clinicians_handbook.pdf. Accessed April 11, 2019.
• Bellack AS, Mueser KT, Gingerich S, Agresta J: Social Skills Training for Schizophrenia: A Step-by-Step Guide, 2nd Edition. New York, Guilford, 2004
• Bellissima BL, Tingle MD, Cicović A, et al: A systematic review of clozapine-induced myocarditis. Int J Cardiol 259:122–129, 2018
• Bellou V, Belbasis L, Tzoulaki I, Evangelou E: Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One 13(3):e0194127, 2018
• Benadryl (diphenhydramine) [prescribing information]. Fort Washington, PA, McNeil Consumer Healthcare, June 2018
• Benztropine injection [prescribing information]. Lake Forest, IL, Akorn, November 2017
• Benztropine tablets [prescribing information]. Livonia, MI, Major Pharmaceuticals, October 2017
• Bergamo C, Sigel K, Mhango G, et al: Inequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study. Psychosom Med 76(3):215–220, 2014
• Bergman H, Soares-Weiser K: Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Jan 17 1(1):CD000204, 2018
• Bergman H, Walker DM, Nikolakopoulou A, et al: Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 21(43):1–218, 2017
• Bergman H, Bhoopathi PS, Soares-Weiser K: Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Jan 20 1(1):CD000205, 2018a
• Bergman H, Rathbone J, Agarwal V, Soares-Weiser K: Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev Feb 6 2(2):CD000459, 2018b
• Berman BD: Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist 1(1):41–47, 2011
• Bertelsen M, Jeppesen P, Petersen L, et al: Suicidal behaviour and mortality in first-episode psychosis: the OPUS trial. Br J Psychiatry Suppl 51:s140–s146, 2007
• Bertilsson L: Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin Pharmacol Ther 82(5):606–609, 2007
• Bhidayasiri R, Fahn S, Weiner WJ, et al; American Academy of Neurology: Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81(5):463–469, 2013
• Bird AM, Smith TL, Walton AE: Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother 45(5):667–675, 2011
• Bishara D, Olofinjana O, Sparshatt A, et al: Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 33(3):329–335, 2013
• Bitter I, Katona L, Zámbori J, et al: Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 23(11):1383–1390, 2013
• Blanchet PJ, Abdillahi O, Beauvais C, et al: Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov Disord 19(8):892–896, 2004
• Bliss SA, Warnock JK: Psychiatric medications: adverse cutaneous drug reactions. Clin Dermatol 31(1):101–109, 2013
• Bolton JM, Morin SN, Majumdar SR, et al: Association of mental disorders and related medication use with risk for major osteoporotic fractures. JAMA Psychiatry 74(6):641–648, 2017
• Bonfioli E, Berti L, Goss C, et al: Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 12:78, 2012
• Bonoldi I, Simeone E, Rocchetti M, et al: Prevalence of self-reported childhood abuse in psychosis: a meta-analysis of retrospective studies. Psychiatry Res 210(1):8–15, 2013
• Borison RL: Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol 6 (suppl 1): S57–S63, 1983
• Bouchama A, Dehbi M, Mohamed G, et al: Prognostic factors in heat wave related deaths: a meta-analysis. Arch Intern Med 167(20):2170–2176, 2007
• Bousman CA, Dunlop BW: Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 18(5):613–622, 2018
• Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L: Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat 11:2125–2142, 2015
• Bower T, Samek DA, Mohammed A, et al: Systemic medication usage in glaucoma patients. Can J Ophthalmol 53(3):242–245, 2018
• Bowie CR, Reichenberg A, Patterson TL, et al: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 163(3):418–425, 2006
• Bowtell M, Eaton S, Thien K, et al: Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res 195:231–236, 2018
• Bradley-Engen MS, Cuddeback GS, Gayman MD, et al: Trends in state prison admission of offenders with serious mental illness. Psychiatr Serv 61(12):1263–1265, 2010
• Braham LG, Trower P, Birchwood M: Acting on command hallucinations and dangerous behavior: a critique of the major findings in the last decade. Clin Psychol Rev 24(5):513–528, 2004
• Brain C, Kymes S, DiBenedetti DB, et al: Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry 18(1):253, 2018 30103719
• Brand RM, McEnery C, Rossell S, et al: Do trauma-focussed psychological interventions have an effect on psychotic symptoms? A systematic review and meta-analysis. Schizophr Res 195:13–22, 2018 28844432
• Brashear A, Ambrosius WT, Eckert GJ, Siemers ER: Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 13(1):158-161, 1998 9452343
• Briggs GG, Freeman RK, Towers CV, Forinash AB: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 11th Edition. Philadelphia, PA, Wolters Kluwer, 2017
• Brito JP, Domecq JP, Murad MH, et al: The Endocrine Society guidelines: when the confidence cart goes before the evidence horse. J Clin Endocrinol Metab 98(8):3246–3252, 2013 23783104
• Bromet EJ, Kotov R, Fochtmann LJ, et al: Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 168(11):1186–1194, 2011
• Bromet EJ, Nock MK, Saha S, et al; World Health Organization World Mental Health Survey Collaborators: Association between psychotic experiences and subsequent suicidal thoughts and behaviors: a cross-national analysis from the World Health Organization World Mental Health Surveys. JAMA Psychiatry 74(11):1136–1144, 2017 28854302
• Brown JD, Barrett A, Caffery E, et al: State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia. Psychiatr Serv 65(1):121–124, 2014 24382765
• Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 177:212–217, 2000
• Browne J, Penn DL, Bauer DJ, et al: Perceived autonomy support in the NIMH RAISE Early Treatment Program. Psychiatr Serv 68(9):916–922, 2017 28566027
• Brunette MF, Mueser KT, Babbin S, et al: Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res 194:4–12, 2018 28697856
• Bruno V, Valiente-Gómez A, Alcoverro O: Clozapine and fever: a case of continued therapy with clozapine. Clin Neuropharmacol 38(4):151–153, 2015 26166236
• Buchanan A, Sint K, Swanson J, Rosenheck R: Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry 176(9):694–701, 2019 Epub ahead of print
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93, 2010
• Buckley L A, Maayan N, Soares-Weiser K, Adams CE: Supportive therapy for schizophrenia. Cochrane Database Syst Rev (4):CD004716, 2015 2587146
• Buckley PF, Schooler NR, Goff DC, et al: Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull 41(2):449–459, 2015 24870446
• Buckley PF, Schooler NR, Goff DC, et al: Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. Psychiatr Serv 67(12):1370–1372, 2016 27476806
• Buhagiar K, Jabbar F: Association of first- vs. second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: a systematic review and meta-analysis. Clin Drug Investig 39(3):253–273, 2019 30675684
• Burke RE, Fahn S, Jankovic J, et al: Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32(12):1335–1346, 1982 6128697
• Burnett AL, Bivalacqua TJ: Priapism: new concepts in medical and surgical management. Urol Clin North Am 38(2):185–194, 2011 21621085
• Burns AM, Erickson DH, Brenner CA: Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv 65(7):874–880, 2014 24686725
• Burns T, Catty J, Becker T, et al; EQOLISE Group: The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial. Lancet 370(9593):1146–1152, 2007 17905167
• Burns T, Rugkåsa J, Molodynski A, et al: Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial. Lancet 381(9878):1627–1633, 2013
• Bush G, Fink M, Petrides G, et al: Catatonia I: rating scale and standardized examination. Acta Psychiatr Scand 93(2):129–136, 1996a
• Bush G, Fink M, Petrides G, et al: Catatonia II: treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 93(2):137–143, 1996b 8686484
• Bushe C, Paton C: The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 19(6 suppl):76–83, 2005 16280340
• Caemmerer J, Correll CU, Maayan L: Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 140(1–3):159–168, 2012 22763424
• Carbon M, Hsieh CH, Kane JM, Correll CU: Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 78(3):e264–e278, 2017 28146614
• Carbon M, Kane JM, Leucht S, Correll CU: Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330–340, 2018 30192088
• Carney R, Cotter J, Firth J, et al: Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. Acta Psychiatr Scand 136(1):5–15, 2017
• Caroff SN, Mann SC: Neuroleptic malignant syndrome. Psychopharmacol Bull 24(1):25–29, 1988 3290944
• Caroff SN, Mann SC, Keck PE Jr, Francis A: Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20(2):257–259, 2000 10770467
• Caroli F, Raymondet P, Izard I, et al: Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence 5:165–171, 2011 21573047
• Carrillo JA, Herraiz AG, Ramos SI, Benítez J: Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 18(4):311–316, 1998 9690697
• Carruthers J, Radigan M, Erlich MD, et al: An initiative to improve clozapine prescribing in New York State. Psychiatr Serv 67(4):369–371, 2016 26725299
• Cassidy RM, Yang F, Kapczinski F, Passos IC: Risk factors for suicidality in patients with schizophrenia: a systematic review, meta-analysis, and meta-regression of 96 studies. Schizophr Bull 44(4):787–797, 2018 29036388
• Castelein S, Bruggeman R, Davidson L, van der Gaag M: Creating a supportive environment: peer support groups for psychotic disorders. Schizophr Bull 41(6):1211–1213, 2015 26297694.
• Catley D, Goggin K, Harris KJ, et al: A randomized trial of motivational interviewing: cessation induction among smokers with low desire to quit. Am J Prev Med 50(5):573–583, 2016 26711164
• Cella M, Preti A, Edwards C, et al: Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev 52:43–51, 2017 27930934
• Cella M, Wykes T: The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. Schizophr Res 203:12–16, 2019 28919130
• Center for Evidence-Based Practices: Assertive community treatment. Cleveland, OH, Case Western Reserve University, 2019. Available at: www.centerforebp.case.edu/practices/act. Accessed March 31, 2019.
• Center for Health Policy/Center for Primary Care and Outcomes Research and Battelle Memorial Institute: Quality Indicator Measure Development, Implementation, Maintenance, and Retirement. Contract No 290-04-0020. Rockville, MD, Agency for Healthcare Research and Quality, May 2011. Available at: www.qualityindicators.ahrq.gov/Downloads/Resources/Publications/2011/QI_Measure_Development_ Implementation_Maintenance_Retirement_Full_5-3-11.pdf. Accessed April 2, 2017.
• Center for Substance Abuse Treatment: Trauma-Informed Care in Behavioral Health Services. Treatment Improvement Protocol (TIP) Series No 57. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2014. Available at: www.ncbi.nlm.nih.gov/books/NBK207201. Accessed May 10, 2019.
• Centers for Disease Control and Prevention: Infection Control Basics: Standard Precautions for All Patient Care. Atlanta, GA, Centers for Disease Control and Prevention, January 26, 2016. Available at: www.cdc.gov/infectioncontrol/basics/standard-precautions.html. Accessed October 4, 2019.
• Centers for Disease Control and Prevention: FAQs Regarding Safe Practices for Medical Injections. Atlanta, GA, Centers for Disease Control and Prevention, June 20, 2019a. Available at: www.cdc.gov/injectionsafety/providers/provider_faqs.html. Accessed July 22, 2020.
• Centers for Disease Control and Prevention: Vaccine Recommendations and Guidelines of the ACIP: Vaccine Administration. Atlanta, GA, Centers for Disease Control and Prevention, June 21, 2019b. Available at: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html. Accessed October 4, 2019.
• Centers for Disease Control and Prevention: Tobacco Use and Quitting Among Individuals With Behavioral Health Conditions. Atlanta, GA, Centers for Disease Control and Prevention, 2020. Available at: www.cdc.gov/tobacco/disparities/mental-illness-substance-use/index.htm. Accessed July 8, 2020.
• Cerovecki A, Musil R, Klimke A, et al: Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27(7):545–572, 2013 23821039
• Challis S, Nielssen O, Harris A, Large M: Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr Scand 127(6):442–454, 2013
• Chapel JM, Ritchey MD, Zhang D, Wang G: Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries. Am J Prev Med 53(6S2):S143–S154, 2017 29153115
• Charzyńska K, Kucharska K, Mortimer A: Does employment promote the process of recovery from schizophrenia? A review of the existing evidence. Int J Occup Med Environ Health 28(3):407–418, 2015 26190722
• Chasser Y, Kim AY, Freudenreich O: Hepatitis C treatment: clinical issues for psychiatrists in the post-interferon era. Psychosomatics 58(1):1–10, 2017
• Chatziralli IP, Sergentanis TN: Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology 118(4):730–735, 2011 21168223
• Chen SY, Ravindran G, Zhang Q, et al: Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs 33(3):225–238, 2019 30758782
• Chien WT, Clifton AV, Zhao S, Lui S: Peer support for people with schizophrenia or other serious mental illness. Cochrane Database Syst Rev April 4 4(4):CD010880, 2019 30946482
• Chisolm MS, Payne JL: Management of psychotropic drugs during pregnancy. BMJ 532:h5918, 2016 26791406
• Chlorpromazine hydrochloride injection [prescribing information]. Deerfield, IL, Baxter, September 2010
• Chlorpromazine hydrochloride injection [prescribing information]. Eatontown, NJ, West-Ward Pharmaceuticals, November 2016
• Chlorpromazine hydrochloride tablets [prescribing information]. Bridgewater, NJ, Amneal Pharmaceuticals, January 2018
• Cho J, Hayes RD, Jewell A, et al: Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 139(3):237–247, 2019
• Chouinard G, Jones B, Remington G, et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13(1):25–40, 1993
• Cimo A, Stergiopoulos E, Cheng C, et al: Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review. BMC Psychiatry 12:24, 2012 22443212
• Citrome L: Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 37(2):138–147, 2017a 28141623
• Citrome L: Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 71(7), 2017b
• Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 52(11):1510–1514, 2001
• Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7(6):377–384, 1987 3323261
• Clarke DE, Wilcox HC, Miller L, et al: Feasibility and acceptability of the DSM-5 Field Trial procedures in the Johns Hopkins Community Psychiatry Programs. Int J Methods Psychiatr Res 23(2):267–278, 2014 24615761
• Clausen W, Watanabe-Galloway S, Baerentzen MB, Britigan DH: Health literacy among people with serious mental illness. Community Ment Health J 52(4):399–405, 2016
• Clayton AH, McGarvey EL, Clavet GJ: The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 33(4):731–745, 1997a 9493486
• Clayton AH, McGarvey EL, Clavet GJ, Piazza L: Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 33(4):747–753, 1997b 9493487
• Cloud DH, Drucker E, Browne A, Parsons J: Public health and solitary confinement in the United States. Am J Public Health 105(1):18–26, 2015 25393185
• Cloutier M, Aigbogun MS, Guerin A, et al: The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 77(6):764–771, 2016 27135986
• Clozapine [prescribing information]. Greenville, NC, Mayne Pharma, June 2017
• Clozapine REMS Program: Recommended monitoring frequency and clinical decisions by ANC level. Phoenix, AZ, Clozapine REMS Program, December 23, 2014. Available at: www.clozapinerems.com/CpmgClozapineUI/ rems/pdf/resources/ANC_Table.pdf. Accessed February 12, 2019.
• Clozapine REMS Program: Prescriber certification. Phoenix, AZ, Clozapine REMS Program, 2019a. Available at: www.clozapinerems.com/CpmgClozapineUI/hcpHome.u. Accessed February 12, 2019.
• Clozapine REMS Program: Program materials: prescriber. Phoenix, AZ, Clozapine REMS Program, 2019b. Available at: www.clozapinerems.com/CpmgClozapineUI/resources.u#tabr4. Accessed February 12, 2019.
• Clozapine REMS Program: Clozapine and the risk of neutropenia: a guide for healthcare providers. Phoenix, AX, Clozpine REMS Program, February 2019c. Available at: www.clozapinerems.com/CpmgClozapineUI/ rems/pdf/resources/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf. Accessed July 14, 2020.
• Clozaril (clozapine) [prescribing information]. East Hanover, NJ, Novartis Pharmaceuticals, January 2017
• Clozaril (clozapine) [product monograph]. Etobicoke, ON, Canada, HLS Therapeutics, July 2019
• Cogentin (benztropine) injection [prescribing information]. Lake Forest, IL, Akorn, May 2013
• Cohen AN, Drapalski AL, Glynn SM, et al: Preferences for family involvement in care among consumers with serious mental illness. Psychiatr Serv 64(3):257–263, 2013 23242515
• Cohen AN, Hamilton AB, Saks ER, et al: How occupationally high-achieving individuals with a diagnosis of schizophrenia manage their symptoms. Psychiatr Serv 68(4):324–329, 2017 27842472
• Coid JW, Ullrich S, Kallis C, et al: The relationship between delusions and violence: findings from the East London first episode psychosis study. JAMA Psychiatry 70(5):465–471, 2013 23467760
• College of Psychiatric and Neurologic Pharmacists: Psychiatric pharmacy essentials: antipsychotic dose equivalents. Lincoln, NE, College of Psychiatric and Neurologic Pharmacists, 2019. Available at: https://cpnp.org/guideline/essentials/antipsychotic-dose-equivalents. Accessed February 25, 2019.
• Conley RR, Kelly DL, Richardson CM, et al: The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 23(6):668–671, 2003 14624201
• Conus P, Cotton S, Schimmelmann BG, et al: Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis. Soc Psychiatry Psychiatr Epidemiol 52(9):1089–1099, 2017 28477070
• Cook BL, Wayne GF, Kafali EN, et al: Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 311(2):172–182, 2014 24399556
• Cook JA, Leff HS, Blyler CR, et al: Results of a multisite randomized trial of supported employment interventions for individuals with severe mental illness. Arch Gen Psychiatry 62(5):505–512, 2005 15867103
• Cookson J, Hodgson R, Wildgust HJ: Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 26(5 suppl):42–51, 2012 22472310
• Copeland ME: Wellness recovery action plan. Occup Ther Ment Health 17:(3–4), 127–150, 2000
• Correll CU, Robinson DG, Schooler NR, et al: Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 71(12):1350–1363, 2014 25321337
• Correll CU, Citrome L, Haddad PM, et al: The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry 77 (suppl 3):1–24, 2016 27732772
• Correll CU, Josiassen RC, Liang GS, et al: Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and mood disorder. Psychopharmacol Bull 47(3):53–60, 2017a 28839340
• Correll CU, Rubio JM, Inczedy-Farkas G, et al: Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7):675–684, 2017b 28514486
• Correll CU, Solmi M, Veronese N, et al: Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16(2):163–180, 2017c
• Correll CU, Rubio JM, Kane JM: What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17(2):149–160, 2018
• Cotton SM, Filia KM, Ratheesh A, et al: Early psychosis research at Orygen, the National Centre of Excellence in Youth Mental Health. Soc Psychiatry Psychiatr Epidemiol 51(1):1–13, 2016 26498752
• Couchman L, Morgan PE, Spencer EP, Flanagan RJ: Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit 32(4):438–447, 2010 20463634
• Coulter C, Baker KK, Margolis RL: Specialized consultation for suspected recent-onset schizophrenia: diagnostic clarity and the distorting impact of anxiety and reported auditory hallucinations. J Psychiatr Pract 25(2):76–81, 2019 30849055
• Council of Medical Specialty Societies: Principles for the Development of Specialty Society Clinical Guidelines. Chicago, IL, Council of Medical Specialty Societies, 2012
• Craig TK, Garety P, Power P, et al: The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 329(7474):1067, 2004 15485934
• Credible Meds: Risk categories for drugs that prolong QT and induce torsades de pointes (TdP). Oro Valley, AZ, Credible Meds, 2019. Available at: https://crediblemeds.org/healthcare-providers/drug-list. Accessed May 6, 2020.
• Creed TA, Stirman SW, Evans AC, Beck AT: A model for implementation of cognitive therapy in community mental health: the Beck Initiative. Behav Ther 37(3):56–64, 2014
• Crockford D, Addington D: Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry 62(9):624–634, 2017
• Crosby AE, Ortega L, Melanson C: Self-Directed Violence Surveillance: Uniform Definitions and Recommended Data Elements, Version 1.0. Atlanta, GA, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, February 2011. Available at: www.cdc.gov/violenceprevention/pdf/self-directed-violence-a.pdf. Accessed May 25, 2015.
• Crow TJ, Cross AJ, Johnstone EC, et al: Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol 2(5):336–340, 1982 7130435
• Cunqueiro A, Durango A, Fein DM, et al: Diagnostic yield of head CT in pediatric emergency department patients with acute psychosis or hallucinations. Pediatr Radiol 49(2):240–244, 2019 30291381
• Czobor P, Van Dorn RA, Citrome L, et al: Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 25(8):1158–1166, 2015 26004980
• D’Amato T, Bation R, Cochet A, et al: A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Schizophr Res 125(2–3):284–290, 2011 21094025
• Daod E, Krivoy A, Shoval G, et al: Psychiatrists’ attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey. Psychiatry Res 275:155–161, 2019 30913436
• Das C, Mendez G, Jagasia S, Labbate LA: Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24(3):225–239, 2012 22860242
• Dauwan M, Begemann MJ, Heringa SM, Sommer IE: Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 42(3):588–599, 2016 26547223
• Davidson M: The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues Clin Neurosci 20(3):215–221, 2018 30581291
• Davis JM, Chen N: Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24(2):192–208, 2004 15206667
• de Boer MK, Castelein S, Wiersma D, et al: A systematic review of instruments to measure sexual functioning in patients using antipsychotics. J Sex Res 51(4):383–389, 2014 24754359
• de Boer MK, Castelein S, Wiersma D, et al: The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 41(3):674–686, 2015 25721311
• De Hert M, Correll CU, Bobes J, et al: Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry 10(1):52–77, 2011 21379357
• De Hert M, Peuskens J, Sabbe T, et al: Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 133(1):5–22, 2016 26114737
• Delahunty A, Morice R: Rehabilitation of frontal/executive impairments in schizophrenia. Aust N Z J Psychiatry 30(6):760–767, 1996 9034464
• de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76(2–3):135–157, 2005
• Depression and Bipolar Support Alliance: Restoring intimacy. Chicago, IL, Depression and Bipolar Support Alliance, 2019. Available at: www.dbsalliance.org/education/related-concerns/sexual-health-and-mood-disorders/restoring-intimacy. Accessed May 6, 2019.
• de Oliveira IR, de Sena EP, Pereira EL, et al: Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther 21(4):229–236, 1996 8933296
• de Silva VA, Suraweera C, Ratnatunga SS, et al: Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 16(1):341, 2016 27716110
• Desmarais JE, Beauclair L, Margolese HC: Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 26(9):1167–1174, 2012 22651987
• Deste G, Barlati S, Cacciani P, et al: Persistence of effectiveness of cognitive remediation interventions in schizophrenia: a 1-year follow-up study. Schizophr Res 161(2–3):403–406, 2015 25533593
• DeTore NR, Hintz K, Khare C, Mueser KT: Disclosure of mental illness to prospective employers: Clinical, psychosocial, and work correlates in persons receiving supported employment. Psychiatry Res 273:312–317, 2019 30677720
• Devinsky O, Pacia SV: Seizures during clozapine therapy. J Clin Psychiatry 55 (suppl B):153–156, 1994 7961562
• Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 41(3):369–371, 1991 2006003
• de Vries B, van Busschbach JT, van der Stouwe ECD, et al: Prevalence rate and risk factors of victimization in adult patients with a psychotic disorder: a systematic review and meta-analysis. Schizophr Bull 45(1):114–126, 2019 29547958
• Dewa CS, Loong D, Trojanowski L, Bonato S: The effectiveness of augmented versus standard individual placement and support programs in terms of employment: a systematic literature review. J Ment Health 27(2):174–183, 2018 28488948
• de With SAJ, Pulit SL, Staal WG, et al: More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J 17(4):304–311, 2017 28418011
• Dickenson R, Momcilovic S, Donnelly L: Anticholinergics vs placebo for neuroleptic-induced parkinsonism. Schizophr Bull 43(1):17, 2017 27585460
• Dickerson F, Schroeder J, Katsafanas E, et al: Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv 69(2):147–153, 2018 28945183
• Diener E, Emmons RA, Larsen RJ, Griffin S: The Satisfaction With Life Scale. J Pers Assess 49(1):71–75, 1985 16367493
• DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE: A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 33(5):599–602, 1976 5066
• Diphenhydramine hydrochloride injection [prescribing information]. Lake Forest, IL, Hospira, May 2019
• Dixon LB, Dickerson F, Bellack AS, et al; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 36(1):48–70, 2010 19955389
• Dixon LB, Lucksted A, Medoff DR, et al: Outcomes of a randomized study of a peer-taught Family-to-Family Education Program for mental illness. Psychiatr Serv 62(6):591–597, 2011 21632725
• Dixon LB, Holoshitz Y, Nossel I: Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry 15(1):13–20, 2016 26833597
• Djulbegovic B, Trikalinos TA, Roback J, et al: Impact of quality of evidence on the strength of recommendations: an empirical study. BMC Health Serv Res 9:120, 2009 19622148
• Dold M, Li C, Tardy M, et al: Benzodiazepines for schizophrenia. Cochrane Database Syst Rev Nov 14 11(11):CD006391, 2012 23152236
• Dold M, Li C, Gillies D, Leucht S: Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23(9):1023–1033, 2013 23602690
• Dold M, Fugger G, Aigner M, et al: Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 166(1–3):187–193, 2015 26008883
• Dollfus S, Lecardeur L, Morello R, Etard O: Placebo response in repetitive transcranial magnetic stimulation trials of treatment of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Bull 42(2):301–308, 2016 26089351
• Dondé C, Vignaud P, Poulet E, et al: Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand 138(4):289–299, 2018 29974451
• Donnelly K, Bracchi R, Hewitt J, et al: Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PloS One 12(4):e0174730, 2017 28448593
• Donoghue K, Doody GA, Murray RM, et al: Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study. Psychiatry Res 215(3):528–532, 2014 24461684
• Donohoe G, Dillon R, Hargreaves A, et al: Effectiveness of a low support, remotely accessible, cognitive remediation training programme for chronic psychosis: cognitive, functional and cortical outcomes from a single blind randomised controlled trial. Psychol Med 48(5):751–764, 2018 28933314
• Dougall N, Maayan N, Soares-Weiser K, et al: Transcranial magnetic stimulation (TMS) for schizophrenia. Cochrane Database Syst Rev Aug 20(8):CD006081, 2015 26289586
• Draine J, Blank Wilson A, Metraux S, et al: The impact of mental illness status on the length of jail detention and the legal mechanism of jail release. Psychiatr Serv 61(5):458–462, 2010 20439365
• Drake R, Skinner J, Goldman HH: What explains the diffusion of treatments for mental illness? Am J Psychiatry 165(11):1385–1392, 2008
• Drake RE, Gates C, Whitaker A, Cotton PG: Suicide among schizophrenics: a review. Compr Psychiatry 26(1):90–100, 1985
• Drapalski AL, Piscitelli S, Lee RJ, et al: Family involvement in the clinical care of clients with first-episode psychosis in the RAISE Connection Program. Psychiatr Serv 69(3):358–361, 2018 29089013
• Druss BG, Bradford DW, Rosenheck RA, et al: Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 283(4):506–511, 2000 10659877
• Druss BG, Zhao L, von Esenwein SA, et al: The Health and Recovery Peer (HARP) Program: a peer-led intervention to improve medical self-management for persons with serious mental illness. Schizophr Res 118(1–3):264–270, 2010 20185272
• Druss BG, Chwastiak L, Kern J, et al: Psychiatry’s role in improving the physical health of patients with serious mental illness: a report from the American Psychiatric Association. Psychiatr Serv 69(3):254–256, 2018 29385957
• Durbin J, Selick A, Langill G, et al: Using fidelity measurement to assess quality of early psychosis intervention services in Ontario. Psychiatr Serv 70(9):840–844, 2019 31159664
• Dyck DG, Short RA, Hendryx MS, et al: Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr Serv 51(4):513–519, 2000 10737828
• Dzahini O, Singh N, Taylor D, Haddad PM: Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol 32(11):1167–1181, 2018 30334664
• Easter MM, Swanson JW, Robertson AG, et al: Facilitation of psychiatric advance directives by peers and clinicians on assertive community treatment teams. Psychiatr Serv 68(7):717–723, 2017 28366114
• Ekström J, Godoy T, Riva A: Clozapine: agonistic and antagonistic salivary secretory actions. J Dent Res 89(3):276–280, 2010 20093673
• Ellison JC, Dufresne RL: A review of the clinical utility of serum clozapine and norclozapine levels. Ment Health Clin 5(2):68–73, 2015
• El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H: Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev (1):CD000458, 2018 29342497
• Essali A, Rihawi A, Altujjar M, et al: Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Cochrane Database Syst Rev Dec 19(12):CD009546, 2013 24353163
• Essock S, Addington D: Coordinated Specialty Care for People With First Episode Psychosis: Assessing Fidelity to the Model. Alexandria, VA, National Association of State Mental Health Program Directors, 2018. Available at: www.nasmhpd.org/sites/default/files/Issue_Brief_Fidelity.pdf. Accessed October 9, 2019.
• Essock SM, Covell NH, Davis SM, et al: Effectiveness of switching antipsychotic medications. Am J Psychiatry 163(12):2090–2095, 2006 17151159
• Eum S, Lee AM, Bishop JR: Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci 18(3):323–337, 2016 27757066
• Every-Palmer S, Ellis PM: Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. CNS Drugs 31(8):699–709, 2017 28623627
• Factor SA, Remington G, Comella CL, et al: The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry 78(9):1344–1350, 2017 29141124
• Fagiolini A, Rocca P, De Giorgi S, et al: Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: randomized controlled trials vs naturalistic studies. Psychiatry Res 247:257–264, 2017 27936437
• Falkenberg I, Benetti S, Raffin M, et al: Clinical utility of magnetic resonance imaging in first-episode psychosis. Br J Psychiatry 211(4):231–237, 2017 28473319
• Fanapt (iloperidone) [prescribing information]. Washington, DC, Vanda Pharmaceuticals, February 2017
• Fann WE, Lake CR: Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 133(8):940–943, 1976 782262
• Farooq S, Choudry A, Cohen D, et al: Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsych Bull 43(1):8–16, 2019 30261942
• Farreny A, Aguado J, Ochoa S, et al: REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res 142(1–3):137–144, 2012 23017827
• FazaClo (clozapine) [prescribing information]. Palo Alto, CA, Jazz Pharmaceuticals, February 2017
• Fazel S, Gulati G, Linsell L, et al: Schizophrenia and violence: systematic review and meta-analysis. PLoS Med 6(8):e1000120, 2009a 19668362
• Fazel S, Långström N, Hjern A, et al: Schizophrenia, substance abuse, and violent crime. JAMA 301(19):2016–2023, 2009b
• Fazel S, Wolf A, Palm C, Lichtenstein P: Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry 1(1):44–54, 2014 25110636
• Fenton WS: Evolving perspectives on individual psychotherapy for schizophrenia. Schizophr Bull 26(1):47–72, 2000 10755669
• Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH: Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 171:265–268, 1997 9337982
• Fernandes-Taylor S, Harris AH: Comparing alternative specifications of quality measures: access to pharmacotherapy for alcohol use disorders. J Subst Abuse Treat 42(1):102–107, 2012
• Fernandez HH, Factor SA, Hauser RA, et al: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 88(21):2003–2010, 2017 28446646
• Ferrando SJ, Owen JA, Levenson JL: Psychopharmacology, in The American Psychiatric Publishing Textbook of Psychiatry, 6th Edition. Edited by Hales RE, Yudofsky SC, Roberts LW. Washington, DC, American Psychiatric Publishing, 2014, pp 929–1003
• Fink M: Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand Suppl 441:1–47, 2013 23215963
• Firth J, Cotter J, Elliott R, et al: A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 45(7):1343–1361, 2015 25650668
• Firth J, Stubbs B, Rosenbaum S, et al: Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43(3):546–556, 2017 27521348
• Firth J, Siddiqi N, Koyanagi A, et al: The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 6(8):675–712, 2019 31324560
• Fleischhacker WW, Kane JM, Geier J et al: Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry 75(3):e184–190, 2014 24717389
• Fluphenazine decanoate injection [prescribing information]. Chestnut Ridge, NY, Par Pharmaceutical, April 2018
• Fluphenazine hydrochloride elixir [prescribing information]. Greenville, SC, Pharmaceutical Associates, December 2016
• Fluphenazine hydrochloride injection [prescribing information]. Schaumburg, IL, APP Pharmaceuticals, September 2010
• Fluphenazine hydrochloride solution, concentrate [prescribing information]. Greenville, SC, PAI, August 2010
• Fluphenazine hydrochloride tablets [prescribing information]. Morgantown, WV, Mylan, November 2016
• Foglia E, Schoeler T, Klamerus E, et al: Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med 47(10):1691–1705, 2017 28179039
• Fond G, Berna F, Boyer L, et al; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group: Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268(1):17–26, 2018 28349247
• Fontanella CA, Campo JV, Phillips GS, et al: Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry 77(5):661–667, 2016 27249075
• Forbes M, Stefler D, Velakoulis D, et al: The clinical utility of structural neuroimaging in first-episode psychosis: a systematic review. Aust N Z J Psychiatry 53(11):1093–1104, 2019 Epub ahead of print
• Fortney JC, Unützer J, Wrenn G, et al: A tipping point for measurement-based care. Psychiatr Serv 68(2):179–188, 2017
• Frank JD, Frank JB: Persuasion and Healing: A Comparative Study of Psychotherapy, 3rd Edition. Baltimore, MD, Johns Hopkins University Press, 1991
• Frederick DE, VanderWeele TJ: Supported employment: meta-analysis and review of randomized controlled trials of individual placement and support. PLoS One 14(2):e0212208, 2019 30785954
• Frei K, Truong DD, Fahn S, et al: The nosology of tardive syndromes. J Neurol Sci 389:10–16, 2018 29433810
• Freudenreich O, Francis A, Fricchione GL: Psychosis, mania, and catatonia, in The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, 3rd Edition. Edited by Levenson JL. Washington, DC, American Psychiatric Association Publishing, 2019, pp 249–279
• Fries BE, Schmorrow A, Lang SW, et al: Symptoms and treatment of mental illness among prisoners: a study of Michigan state prisons. Int J Law Psychiatry 36(3–4):316–325, 2013 23688801
• Froes Brandao D, Strasser-Weippl K, Goss PE: Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review. Cancer 122(2):184–188, 2016 26457577
• Fung WL, Butcher NJ, Costain G, et al: Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med 17(8):599–609, 2015 25569435
• Funk MC, Beach SR, Bostwick JR, et al: Resource document on QTc prolongation and psychotropic medications. APA Resource Document. Washington, DC, American Psychiatric Association, 2018. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/resource_ documents/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf. Accessed December 7, 2018.
• Fusar-Poli P, Cappucciati M, Borgwardt S, et al: Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry 73(2):113–120, 2016 26719911
• Gabbard GO: Techniques of psychodynamic psychotherapy, in Textbook of Psychotherapeutic Treatments. Edited by Gabbard GO. Washington, DC, American Psychiatric Publishing, 2009, pp 43–67
• Gaebel W, Riesbeck M, von Wilmsdorff M, et al; EUFEST Study Group: Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 20(5):310–316, 2010 20202800
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al: Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19(1):69–76, 2017 27388693
• Gaedigk A, Ingelman-Sundberg M, Miller NA, et al; PharmVar Steering Committee:Tthe Pharmacogene Variation (PharmVar) Consortium: incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther 103(3):399–401, 2018 29134625
• Galletly C, Castle D, Dark F, et al: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50(5):410–472, 2016
• Galling B, Roldán A, Hagi K, et al: Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16(1):77–89, 2017 28127934
• Ganesh M, Jabbar U, Iskander FH: Acute laryngeal dystonia with novel antipsychotics: a case report and review of literature. J Clin Psychopharmacol 35(5):613–615, 2015 26252439
• Gao K, Fang F, Wang Z, Calabrese JR: Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder. J Clin Psychopharmacol 36(6):637–642, 2016 27753728
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al: Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36(4):355–371, 2016 27307187
• Garety PA, Fowler DG, Freeman D, et al: Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br J Psychiatry 192(6):412–423, 2008 18515890
• Gaynes BN, Brown C, Lux LJ, et al: Management Strategies to Reduce Psychiatric Readmissions (Technical Brief No 21, AHRQ Publ No 15-EHC018-EF). Rockville, MD, Agency for Healthcare Research and Quality, May 2015. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed October 3, 2019.
• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858, 2018 30496104
• Gee SH, Shergill SS, Taylor DM: Patient attitudes to clozapine initiation. Int Clin Psychopharmacol 32(6):337–342, 2017 28704228
• Geodon (ziprasidone) [prescribing information]. New York, Pfizer, November 2018
• Gertner AK, Grabert B, Domino ME, et al: The effect of referral to expedited Medicaid on substance use treatment utilization among people with serious mental illness released from prison. J Subst Abuse Treat 99:9–15, 2019 30797401
• Ghany MG, Hoofnagle JH: Approach to the patient with liver disease, in Harrison’s Principles of Internal Medicine, 20th Edition. Edited by Jameson J, Fauci AS, Kasper DL, et al. New York, McGraw-Hill, 2018. Available at: https://accessmedicine.mhmedical.com/content.aspx?bookid=2129&sectionid=192283281. Accessed May 6, 2020.
• Gibson LM, Paul L, Chappell FM, et al: Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis. BMJ 363:k4577, 2018 30467245
• Gierisch JM, Nieuwsma JA, Bradford DW, et al: Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 75(5):e424–e440, 2014 24922495
• Glowa-Kollisch S, Kaba F, Waters A, et al: From punishment to treatment: the “Clinical Alternative to Punitive Segregation” (CAPS) program in New York City jails. Int J Environ Res Public Health 13(2):182, 2016 26848667
• Glynn SM, Marder SR, Liberman RP, et al: Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry 159(5):829–837, 2002 11986138
• Glynn SM, Cather C, Gingerich S, et al: NAVIGATE Family Education Program, April 1, 2014. Available at: http://www.navigateconsultants.org/wp-content/uploads/2017/05/FE-Manual.pdf. Accessed October 9, 2019.
• Godwin-Austen RB, Clark T: Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J 4(5778):25–26, 1971 4938245
• Goff DC, Arana GW, Greenblatt DJ, et al: The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 11(2):106–112, 1991 2056136
• Goff DC, Falkai P, Fleischhacker WW, et al: The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 74(9):840–849, 2017 28472900
• Goldberg RW, Dickerson F, Lucksted A, et al: Living Well: an intervention to improve self-management of medical illness for individuals with serious mental illness. Psychiatr Serv 64(1):51–57, 2013 23070062
• Gomar JJ, Valls E, Radua J, et al; Cognitive Rehabilitation Study Group: A multisite, randomized controlled clinical trial of computerized cognitive remediation therapy for schizophrenia. Schizophr Bull 41(6):1387–1396, 2015 26006264
• Grady PA, Gough LL: Self-management: a comprehensive approach to management of chronic conditions. Am J Public Health 104(8):e25–e31, 2014 24922170
• Granholm EL, McQuaid JR, Holden JL: Cognitive-Behavioral Social Skills Training for Schizophrenia: A Practical Treatment Guide. New York, Guilford, 2016
• Graus F, Titulaer MJ, Balu R, et al: A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404, 2016 26906964
• Gray GE, Pi EH: Ethnicity and medication-induced movement disorders. J. Practical Psychiatry 4(5):259–264, 1998
• Green MF: Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry 77 (suppl 2):8–11, 2016 26919052
• Greenblatt DJ, DiMascio A, Harmatz JS, et al: Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol 17(11–12):704–708, 1977 336651
• Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, et al: Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res 179:57–63, 2017 27743650
• Greenhalgh T, Robert G, Macfarlane F, et al: Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q 82(4):581–629, 2004
• Gregory A, Mallikarjun P, Upthegrove R: Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 211(4):198–204, 2017 28882827
• Grigg J, Worsley R, Thew C, et al: Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl) 234(22):3279–3297, 2017 28889207
• Grover S, Hazari N, Kate N: Combined use of clozapine and ECT: a review. Acta Neuropsychiatr 27(3):131–142, 2015 25697225
• Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):e285–e350, 2018 30423393
• Guenette MD, Hahn M, Cohn TA, et al: Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl) 226(1):1–12, 2013 23344556
• Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72(9):1222–1228, 2011 21733489
• Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN: A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 37(1):67–71, 2017
• Guy W (ed): ECDEU Assessment Manual for Psychopharmacology (Publ ADM 76-338.) Washington, DC, Center for Quality Assessment and Improvement in Mental Health, U.S. Department of Health, Education, and Welfare, 1976
• Guyatt G, Gutterman D, Baumann MH, et al: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129(1):174–181, 2006 16424429
• Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group: Going from evidence to recommendations. BMJ 336(7652):1049–1051, 2008
• Guyatt G, Eikelboom JW, Akl EA, et al: A guide to GRADE guidelines for the readers of JTH. J Thromb Haemost 11(8):1603–1608, 2013 23773710
• Haddad PM, Brain C, Scott J: Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 5:43–62, 2014 25061342
• Haldol decanoate injection (haloperidol) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, March 2019
• Haldol lactate injection (haloperidol) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, March 2019
• Hall D, Lee LW, Manseau MW, et al: Major mental illness as a risk factor for incarceration. Psychiatr Serv 70(12):1088–1093, 2019 31480926
• Haloperidol [prescribing information]. Princeton, NJ, Sandoz, September 2008
• Haloperidol lactate [prescribing information]. Greenville, SC, Pharmaceutical Associates, December 2008
• Haloperidol lactate injection [prescribing information]. Schaumburg, IL, Sagent Pharmaceuticals, August 2011
• Haloperidol lactate oral solution [prescribing information]. Greenville, SC, Pharmaceutical Associates, November 2016
• Haloperidol tablets [prescribing information]. Princeton, NJ, Sandoz, July 2015
• Hamann GL, Egan TM, Wells BG, Grimmig JE: Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 51(12):502–504, 1990 1979555
• Hamann J, Heres S: Why and how family caregivers should participate in shared decision making in mental health. Psychiatr Serv 70(5):418–421, 2019 30784381
• Hamann J, Mendel R, Heres S, et al: How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol 20(4):276–279, 2010 20133108
• Hamann J, Kissling W, Heres S: Checking the plausibility of psychiatrists? Arguments for not prescribing depot medication. Eur Neuropsychopharmacol 24(9):1506–1510, 2014 25037772
• Harding KJ, Rush AJ, Arbuckle M, et al: Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry 72(8):1136–1143, 2011
• Hardy K: Cognitive behavioral therapy for psychosis (CBTp). Alexandria, VA, National Association of State Mental Health Program Directors, 2019. Available at: www.nasmhpd.org/sites/default/files/DH-CBTp_ Fact_Sheet.pdf. Accessed April 12, 2019.
• Harkavy-Friedman JM, Kimhy D, Nelson EA, et al: Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. J Clin Psychiatry 64(8):871–874, 2003 12927000
• Harris A, Chen W, Jones S, et al: Community treatment orders increase community care and delay readmission while in force: results from a large population-based study. Aust N Z J Psychiatry 53(3):228–235, 2019 29485289
• Hartung D, Low A, Jindai K, et al: Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: a systematic review. Psychosomatics 58(2):101–112, 2017 28139249
• Hartz SM, Pato CN, Medeiros H, et al; Genomic Psychiatry Cohort Consortium: Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71(3):248–254, 2014 24382686
• Harvey PD: Assessment of everyday functioning in schizophrenia. Innov Clin Neurosci 8(5):21–24, 2011 21686144
• Harvey PD, McGurk SR, Mahncke H, Wykes T: Controversies in computerized cognitive training. Biol Psychiatry Cogn Neurosci Neuroimaging 3(11):907–915, 2018 30197048
• Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13(5):318–378, 2012
• Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14(1):2–44, 2013
• Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16(3):142–170, 2015
• Hasson-Ohayon I, Roe D, Kravetz S: A randomized controlled trial of the effectiveness of the Illness Management and Recovery Program. Psychiatr Serv 58(11):1461–1466, 2007 17978257
• Hatch A, Docherty JP, Carpenter D, et al: Expert consensus survey on medication adherence in psychiatric patients and use of a digital medicine system. J Clin Psychiatry 78(7):e803–e812, 2017 28541648
• Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA: Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord 32:124–126, 2016 27622970
• Hauser P, Kern S: Psychiatric and substance use disorders co-morbidities and hepatitis C: diagnostic and treatment implications. World J Hepatol 7(15):1921–1935, 2015
• Hauser RA, Factor SA, Marder SR, et al: KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174(5):476–484, 2017 28320223
• Hauser RA, Fernandez HH, Stamler D, et al: 45 Long-term treatment with deutetrabenazine is associated with continued improvement in tardive dyskinesia: results from an open-label extension study. CNS Spectr 24(1):200–201, 2019 30859973
• Hawton K, Sutton L, Haw C, et al: Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187:9–20, 2005
• Hayes JF, Marston L, Walters K, et al: Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry 211(3):175–181, 2017 28684403
• Hazlehurst JM, Armstrong MJ, Sherlock M, et al: A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) 78(2):183–190, 2013 22624723
• He H, Lu J, Yang L, et al: Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: a PRISMA compliant meta-analysis. Clin Neurophysiol 128(5):716–724, 2017 28315614
• He M, Deng C, Huang XF: The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 27(6):423–434, 2013 23640535
• Heilä H, Haukka J, Suvisaari J, Lönnqvist J: Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 35(5):725–732, 2005 15918349
• Helfer B, Samara MT, Huhn M, et al: Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173(9):876–886, 2016 27282362
• Helle S, Ringen PA, Melle I, et al: Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119). Schizophr Res 170(1):217–221, 2016 26682958
• Henderson DC, Vincenzi B, Andrea NV, et al: Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2(5):452–464, 2015
• Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67(12):1948–1953, 2006 17194274
• Heres S, Schmitz FS, Leucht S, Pajonk FG: The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22(5):275–282, 2007 17690596
• Heres S, Frobose T, Hamann J, et al: Patients’ acceptance of the deltoid application of risperidone long-acting injection. Eur Neuropsychopharmacol 22(12):897–901, 2012 22578781
• Hiemke C, Dragicevic A, Gründer G, et al: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26(2):156–160, 2004 15228157
• Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62, 2018 28910830
• Higashi K, Medic G, Littlewood KJ, et al: Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3(4):200–218, 2013 24167693
• Higgins JM, San C, Lagnado G, et al: Incidence and management of clozapine-induced myocarditis in a large tertiary hospital. Can J Psychiatry 64(8):561–567, 2019
• Hirsch L, Yang J, Bresee L, et al: Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40(9):771–781, 2017 28585153
• Hirschtritt ME, Delucchi KL, Olfson M: Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993–2014. Prev Med Rep 9:49–54, 2017 29340270
• Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M: Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4(4):295–301, 2017 28237639
• Hobkirk AL, Towe SL, Lion R, Meade CS: Primary and secondary HIV prevention among persons with severe mental illness: recent findings. Curr HIV/AIDS Rep 12(4):406–412, 2015
• Hoffmann H, Jäckel D, Glauser S, et al: Long-term effectiveness of supported employment: 5-year follow-up of a randomized controlled trial. Am J Psychiatry 171(11):1183–1190, 2014 25124692
• Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, et al: Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Am J Psychiatry 154(11):1504–1513, 1997 9356557
• Holt RI, Mitchell AJ: Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 11(2):79–89, 2015 25445848
• Honigfeld G, Arellano F, Sethi J, et al: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 (suppl 3):3–7, 1998 9541331
• Hor K, Taylor M: Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 24(4) (suppl):81–90, 2010
• Horvitz-Lennon M, Donohue JM, Domino ME, Normand SL: Improving quality and diffusing best practices: the case of schizophrenia. Health Aff (Millwood) 28(3):701–712, 2009
• Horvitz-Lennon M, Mattke S, Predmore Z, Howes OD: The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry 174(5):421–426, 2017 28457153
• Howard R, Rabins PV, Seeman MV, Jeste DV: Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus: the International Late-Onset Schizophrenia Group. Am J Psychiatry 157(2):172–178, 2000 10671383
• Howells FM, Kingdon DG, Baldwin DS: Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Hum Psychopharmacol 32(5), 2017
• Howes OD, McCutcheon R, Agid O, et al: Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174(3):216–229, 2017 27919182
• Hughes E, Bassi S, Gilbody S, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 3(1):40–48, 2016
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951, 2019 31303314 [Erratum Lancet 394(10202):918, 2019 31526735]
• Huhtaniska S, Jääskeläinen E, Hirvonen N, et al: Long-term antipsychotic use and brain changes in schizophrenia—a systematic review and meta-analysis. Hum Psychopharmacol 32(2), 2017
• Hui CLM, Honer WG, Lee EHM, et al: Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 5(5):432–442, 2018 29551618
• Hunt GE, Siegfried N, Morley K, et al: Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev Oct 3(10):CD001088, 2013 24092525
• Hunt GE, Large MM, Cleary M, et al: Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug Alcohol Depend 191:234–258, 2018 30153606
• Hynes C, Keating D, McWilliams S, et al: Glasgow Antipsychotic Side-effects Scale for clozapine: development and validation of a clozapine-specific side-effects scale. Schizophr Res 168(1–2):505–513, 2015 26276305
• Ince P, Haddock G, Tai S: A systematic review of the implementation of recommended psychological interventions for schizophrenia: rates, barriers, and improvement strategies. Psychol Psychother 89(3):324–350, 2016 26537838
• Ingrezza (valbenazine) [prescribing information]. San Diego, CA, Neurocrine Biosciences, July 2019
• Inskip HM, Harris EC, Barraclough B: Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 172:35–37, 1998
• Institute of Medicine: Improving the Quality of Health Care for Mental and Substance-Use Conditions. Washington, DC, National Academies Press, 2006. Available at: https://doi.org/10.17226/11470. Accessed October 3, 2019.
• Institute of Medicine: Clinical Practice Guidelines We Can Trust. Washington, DC, National Academies Press, 2011
• Institute of Medicine Committee on Quality of Health Care in America: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC, National Academies Press, 2001. Available at: www.ncbi.nlm.nih.gov/books/NBK222274. Accessed March 28, 2017.
• Invega (paliperidone) [product monograph]. Toronto, ON, Canada, Janssen, September 2018
• Invega (paliperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, January 2019
• Invega Sustenna (paliperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, July 2018a
• Invega Sustenna (paliperidone) [product monograph]. Toronto, ON, Canada, Janssen, September 2018b
• Invega Trinza (paliperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, July 2018a
• Invega Trinza (paliperidone) [product monograph]. Toronto, ON, Canada, Janssen, September 2018b
• Iorfino F, Scott EM, Carpenter JS, et al: Clinical stage transitions in persons aged 12 to 25 years presenting to early intervention mental health services with anxiety, mood, and psychotic disorders. JAMA Psychiatry Aug 28, 2019 Epub ahead of print
• Ismail Z, Wessels AM, Uchida H, et al: Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry 20(1):53–60, 2012 21422906
• Iyer S, Banks N, Roy MA, et al: A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics, part I: patient perspectives. Can J Psychiatry 58(5 suppl 1):14S–22S, 2013 23945063
• Iyer SP, Spaeth-Rublee B, Pincus HA: Challenges in the operationalization of mental health quality measures: an assessment of alternatives. Psychiatr Serv 67(10):1057–1059, 2016
• Jahshan C, Vinogradov S, Wynn JK, et al: A randomized controlled trial comparing a “bottom-up” and “top-down” approach to cognitive training in schizophrenia. J Psychiatr Res 109:118–125, 2019 30529836
• Jann MW, Ereshefsky L, Saklad SR: Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10(4):315–333, 1985 2864156
• Janssen EM, McGinty EE, Azrin ST, et al: Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry 37(3):199–222, 2015 25881768
• Jauhar S, McKenna PJ, Radua J, et al: Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204(1):20–29, 2014 24385461
• Jehan S, Myers AK, Zizi F, et al: Obesity, obstructive sleep apnea and type 2 diabetes mellitus: epidemiology and pathophysiologic insights. Sleep Med Disord 2(3):52–58, 2018 30167574
• Jensen KG, Correll CU, Rudå D, et al: Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) trial. J Am Acad Child Adolesc Psychiatry 58(11):1062–1078, 2019 30858012
• Jin H, Mosweu I: The societal cost of schizophrenia: a systematic review. Pharmacoeconomics 35(1):25–42, 2017 27557994
• Jinnah HA, Factor SA: Diagnosis and treatment of dystonia. Neurol Clin 33(1):77–100, 2015 25432724
• Jordan G, Lutgens D, Joober R, et al: The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry 75(6):e566–e572, 2014
• Josiassen RC, Kane JM, Liang GS, et al: Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull 47(3):61–68, 2017 28839341
• Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al: Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 234(17):2563–2570, 2017 28567698
• Kaba F, Lewis A, Glowa-Kollisch S, et al: Solitary confinement and risk of self-harm among jail inmates. Am J Public Health 104(3):442–447, 2014 24521238
• Kahn RS, Winter van Rossum I, Leucht S, et al; OPTiMiSE study group: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 5(10):797–807, 2018 30115598
• Kaiser RM: Physiological and clinical considerations of geriatric patient care, in The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 5th Edition. Edited by Steffens DC, Blazer DG, Thakur ME. Arlington, VA, American Psychiatric Publishing, 2015, pp 33–59
• Kalachnik JE, Sprague RL: The Dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations. J Clin Psychol 49(2):177–189, 1993 8098048
• Kane JM, Marder SR, Schooler NR, et al: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 58(10):965–972, 2001 11576036
• Kane JM, Kishimoto T, Correll CU: Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12(3):216–226, 2013 24096780
• Kane JM, Correll CU, Liang GS, et al: Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder. Psychopharmacol Bull 47(3):69–76, 2017 28839342
• Kane JM, Schooler NR, Marcy P, et al: Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry 80(3):18m12546, 2019 31050233
• Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Mov Disord 1(3):193–208, 1986 2904118
• Kaplan J, Schwartz AC, Ward MC: Clozapine-associated aspiration pneumonia: case series and review of the literature. Psychosomatics 59(2):199–203, 2018 28992957
• Kapoor R, Trestman R: Mental health effects of restrictive housing, in Restrictive Housing in the U.S.: Issues, Challenges, and Future Directions. Washington, DC, National Institute of Justice, 2016, pp 199–232. Available at www.ncjrs.gov/pdffiles1/nij/250315.pdf. Accessed October 4, 2019.
• Kates J, Rockland LH: Supportive psychotherapy of the schizophrenic patient. Am J Psychother 48(4):543–561, 1994 7872417
• Kato Y, Umetsu R, Abe J, et al: Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci 1:15, 2015 26819726
• Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276, 1987
• Kazamatsuri H, Chien C, Cole JO: Treatment of tardive dyskinesia, I: clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 27(1):95–99, 1972 4555831
• Keck PEJr, Pope HG Jr, Cohen BM, et al: Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 46(10):914–918, 1989 2572206
• Keefe RS, Vinogradov S, Medalia A, et al: Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry 73(7):1016–1022, 2012 22687548
• Keers R, Ullrich S, Destavola BL, Coid JW: Association of violence with emergence of persecutory delusions in untreated schizophrenia. Am J Psychiatry 171(3):332–339, 2014 24220644
• Keller A, McGarvey EL, Clayton AH: Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 32(1):43–52, 2006 16234225
• Keller WR, Fischer BA, McMahon R, et al: Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis 202(1):6–12, 2014 24375205
• Kelley ME, Wan CR, Broussard B, et al: Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res 171(1–3):62–67, 2016 26785806
• Kelly DL, Freudenreich O, Sayer MA, Love RC: Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 69(2):224–227, 2018 29032704
• Kelly DL, Love RC: Psychiatric pharmacist’s role in overcoming barriers to clozapine use and improving management. Ment Health Clin 9(2):64–69, 2019 30842912
• Kelly JT, Zimmermann RL, Abuzzahab FS, Schiele BC: A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology 12(2):65–73, 1974 4610599
• Kemp K, Zelle H, Bonnie RJ: Embedding advance directives in routine care for persons with serious mental illness: implementation challenges. Psychiatr Serv 66(1):10–14, 2015 25554232
• Kennedy JL, Altar CA, Taylor DL, et al: The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 29(2):63–76, 2014 23995856
• Khan AA, Ashraf A, Baker D, et al: Clozapine and incidence of myocarditis and sudden death—long term Australian experience. Int J Cardiol 238:136–139, 2017 28343762
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3(1):1–150, 2013
• Kingdon D, Turkington D: CBT for psychosis: approaches families can use. Arlington, VA, National Alliance on Mental Illness, April 15, 2019. Available at: https://nami.org/Blogs/NAMI-Blog/April-2019/CBT-for-Psychosis-Approaches-Families-Can-Use. Accessed April 21, 2019.
• Kinon BJ, Gilmore JA, Liu H, Halbreich UM: Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (suppl s):55–68, 2003 12650681
• Kinoshita Y, Furukawa TA, Kinoshita K, et al: Supported employment for adults with severe mental illness. Cochrane Database Syst Rev Sep 13(9):CD008297, 2013 24030739
• Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD: The natural history of tardive dystonia: a long-term follow-up study of 107 cases. Brain 121 (Pt 11):2053–2066, 1998 9827766
• Kirino E: Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Ann Gen Psychiatry 16:43, 2017 29209406
• Kirschner M, Theodoridou A, Fusar-Poli P, et al: Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 3(2):89–99, 2013 24167680
• Kirsh B: Client, contextual and program elements influencing supported employment: a literature review. Community Ment Health J 52(7):809–820, 2016 27055809
• Kisely S, Smith M, Lawrence D, et al: Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 176(6):779–784, 2007 17353530
• Kisely S, Crowe E, Lawrence D: Cancer-related mortality in people with mental illness. JAMA Psychiatry 70(2):209–217, 2013 23247556
• Kisely S, Baghaie H, Lalloo R, et al: A systematic review and meta-analysis of the association between poor oral health and severe mental illness. Psychosom Med 77(1):83–92, 2015
• Kishi T, Matsunaga S, Iwata N: Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials. Schizophr Bull 42(6):1438–1445, 2016a 27086079
• Kishi T, Oya K, Iwata N: Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trials. Psychiatry Res 246:750–755, 2016b 27863801
• Kishi T, Ikuta T, Matsui Y, et al: Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med 49(5):772–779, 2019 29909790
• Kishimoto T, Nitta M, Borenstein M, et al: Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10):957–965, 2013 24229745
• Kishimoto T, Robenzadeh A, Leucht C, et al: Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40(1):192–213, 2014 23256986
• Kishimoto T, Hagi K, Nitta M, et al: Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull 44(3):603–619, 2018 29868849
• Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, et al: Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 150(1):274–280, 2013 23953217
• Klil-Drori AJ, Yin H, Abenhaim HA, et al: Prolactin-elevating antipsychotics and the risk of endometrial cancer. J Clin Psychiatry 78(6):714–719, 2017 28199787
• Knegtering H, van den Bosch R, Castelein S, et al: Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 33(6):711–717, 2008 18395353
• Knoph KN, Morgan RJ III, Palmer BA, et al: Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophr Res 199:17–30, 2018 29548760
• Koek RJ, Pi EH: Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 30(4):359–364, 1989 2572029
• König P, Chwatal K, Havelec L, et al: Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 33(2):80–84, 1996 8927233
• Koopmans AB, Vinkers DJ, Poulina IT, et al: No effect of dose adjustment to the CYP2D6 genotype in patients with severe mental illness. Front Psychiatry 9:349, 2018 30131727
• Kopelovich SL, Hughes M, Monroe-DeVita MB, et al: Statewide implementation of cognitive behavioral therapy for psychosis through a learning collaborative model. Cognit Behav Pract 26(3):439–452, 2019a
• Kopelovich SL, Strachan E, Sivec H, Kreider V: Stepped care as an implementation and service delivery model for cognitive behavioral therapy for psychosis. Community Ment Health J 55(5):755–767, 2019b 30623294
• Kopelowicz A, Liberman RP, Zarate R: Recent advances in social skills training for schizophrenia. Schizophr Bull 32 (suppl 1):S12–S23, 2006 16885207
• Kopelowicz A, Zarate R, Wallace CJ, et al: The ability of multifamily groups to improve treatment adherence in Mexican Americans with schizophrenia. Arch Gen Psychiatry 69(3):265–273, 2012 22393219
• Koskinen J, Löhönen J, Koponen H, et al: Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36(6):1115–1130, 2010
• Kotin J, Wilbert DE, Verburg D, Soldinger SM: Thioridazine and sexual dysfunction. Am J Psychiatry 133(1):82–85, 1976 1247127
• Koytchev R, Alken RG, McKay G, Katzarov T: Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol 51(2):183–187, 1996 8911886
• Krakowski MI, Czobor P, Citrome L, et al: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 63(6):622–629, 2006 16754835
• Krakowski MI, Czobor P, Nolan KA: Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 28(5):485–493, 2008 18794642
• Krelstein MS: The role of mental health in the inmate disciplinary process: a national survey. J Am Acad Psychiatry Law 30(4):488–496, 2002
• Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT): The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36(1):94–103, 2010
• Kreyenbuhl J, Record EJ, Palmer-Bacon J: A review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialogues Clin Neurosci 18(2):191–201, 2016 27489459
• Kroeze WK, Hufeisen SJ, Popadak BA, et al: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519–526, 2003 12629531
• Kroon LA: Drug interactions with smoking. Am J Health Syst Pharm 64(18):1917–1921, 2007
• Kugathasan P, Horsdal HT, Aagaard J, et al: Association of secondary preventive cardiovascular treatment after myocardial infarction with mortality among patients with schizophrenia. JAMA Psychiatry 75(12):1234–1240, 2018 30422158
• Kuhnigk O, Slawik L, Meyer J, et al: Valuation and attainment of treatment goals in schizophrenia: perspectives of patients, relatives, physicians, and payers. J Psychiatr Pract 18(5):321–328, 2012 22995959
• Kukla M, Bell MD, Lysaker PH: A randomized controlled trial examining a cognitive behavioral therapy intervention enhanced with cognitive remediation to improve work and neurocognition outcomes among persons with schizophrenia spectrum disorders. Schizophr Res 197:400–406, 2018 29422299
• Lachkar Y, Bouassida W: Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 18(2):129–133, 2007 17301614
• Lagishetty CV, Deng J, Lesko LJ, et al: How informative are drug-drug interactions of gene-drug interactions? J Clin Pharmacol 56(10):1221–1231, 2016 27040602
• La Grenade L, Graham D, Trontell A: Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 345(3):224–225, 2001 11463031
• Lally J, Docherty MJ, MacCabe JH: Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database Syst Rev Jun 9(6):CD011566, 2016a 27277334
• Lally J, Tully J, Robertson D, et al: Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224, 2016b 26827129
• Lally J, Ajnakina O, Stubbs B, et al: Hyperprolactinaemia in first episode psychosis: a longitudinal assessment. Schizophr Res 189:117–125, 2017a 28755878
• Lally J, Malik S, Krivoy A, et al: The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. J Clin Psychopharmacol 37(5):600–604, 2017b 28817489
• Lally J, Malik S, Whiskey E, et al: Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol 37(4):441–446, 2017c 28437295
• Land R, Siskind D, McArdle P, et al: The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135(4):296–309, 2017 28155220
• Landa Y: Cognitive behavioral therapy for psychosis (CBTp): an introductory manual for clinicians. New York, MIRECC VISN 2, 2019. Available at: www.mirecc.va.gov/visn2/docs/CBTp_Manual_VA_Yulia_Landa_ 2017.pdf. Accessed April 1, 2019.
• Large MM, Nielssen O: Violence in first-episode psychosis: a systematic review and meta-analysis. Schizophr Res 125(2–3):209–220, 2011
• Large M, Sharma S, Compton MT, et al: Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 68(6):555–561, 2011
• Large M, Mullin K, Gupta P, et al: Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry 48(5):418–432, 2014
• Lariscy JT, Hummer RA, Rogers RG: Cigarette smoking and all-cause and cause-specific adult mortality in the United States. Demography 55(5):1855–1885, 2018 30232778
• Laties AM, Flach AJ, Baldycheva I, et al: Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. J Psychopharmacol 29(1):69–79, 2015 25315830
• Latimer E, Wynant W, Clark R, et al: Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec. Clin Schizophr Relat Psychoses 7(1):33–41, 2013 23367500
• La Torre A, Conca A, Duffy D, et al: Sexual dysfunction related to psychotropic drugs: a critical review, part II: antipsychotics. Pharmacopsychiatry 46(6):201–208, 2013 23737244
• Latuda (lurasidone) [prescribing information]. Marlborough, MA, Sunovion Pharmaceuticals, March 2018
• Lauby-Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer Handbook Working Group: Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med 375(8):794–798, 2016 27557308
• Laursen TM, Wahlbeck K, Hällgren J, et al: Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 8(6):e67133, 2013
• Laursen TM, Nordentoft M, Mortensen PB: Excess early mortality in schizophrenia. Annu Rev Clin Psychol 10:425–448, 2014 24313570
• Lawrence D, Kisely S, Pais J: The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 55(12):752–760, 2010 21172095
• Lawson W, Johnston S, Karson C, et al: Racial differences in antipsychotic use: claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry 27(4):242–252, 2015 26554365
• Lean M, Fornells-Ambrojo M, Milton A, et al: Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 214(5):260–268, 2019 30898177
• Le Boutillier C, Leamy M, Bird VJ, et al: What does recovery mean in practice? A qualitative analysis of international recovery-oriented practice guidance. Psychiatr Serv 62(12):1470–1476, 2011
• Lecomte T, Leclerc C, Wykes T: Group CBT for Psychosis: A Guidebook for Clinicians. New York, Oxford University Press, 2016, p 296
• Lee EE, Liu J, Tu X, et al: A widening longevity gap between people with schizophrenia and general population: a literature review and call for action. Schizophr Res 196:9–13, 2018 28964652
• Lee WM, Stravitz RT, Larson AM: AASLD position paper: the management of acute liver failure: update 2011. Alexandria, VA, American Association for the Study of Liver Diseases, 2011. Available at: www.aasld.org/sites/default/files/2019-06/AcuteLiverFailureUpdate201journalformat1.pdf. Accessed March 31, 2017.
• Legge SE, Hamshere ML, Ripke S, et al: Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 22(10):1502–1508, 2017 27400856
• Leucht S, Kane JM, Kissling W, et al: Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 187:366–371, 2005 16199797
• Leucht S, Tardy M, Komossa K, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071, 2012 22560607
• Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962, 2013 23810019
• Leucht S, Samara M, Heres S, et al: Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2):314–326, 2014 24493852
• Leucht S, Samara M, Heres S, et al: Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 41(6):1397–1402, 2015 25841041
• Leucht S, Leucht C, Huhn M, et al: Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942, 2017 28541090
• Leung JG, Breden EL: Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 45(4):525–531, 2011 21487088
• Leung JG, Hasassri ME, Barreto JN, et al: Characterization of admission types in medically hospitalized patients prescribed clozapine. Psychosomatics 58(2):164–172, 2017 28153339
• Leung JG, Cusimano J, Gannon JM, et al: Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey. Int Clin Psychopharmacol 34(5):247–256, 2019 31107831
• Levitan B, Markowitz M, Mohamed AF, et al: Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv 66(7):719–726, 2015 25772762
• Levounis P, Arnaout B, Marienfeld C: Motivational Interviewing for Clinical Practice. Arlington, VA, American Psychiatric Association Publishing, 2017
• Lewis CC, Boyd M, Puspitasari A, et al: Implementing measurement-based care in behavioral health: a review. JAMA Psychiatry 76(3):324–335, 2019 30566197
• Lewis-Fernández R, Aggarwal NK, Hinton L, et al (eds): DSM-5® Handbook on the Cultural Formulation Interview. Arlington, VA, American Psychiatric Association Publishing, 2016
• Lexicomp: Lexicomp database. Riverwoods IL, Wolters Kluwer Health, 2019. Available at: http://online.lexi.com. Accessed January 4, 2019.
• Liang CS, Ho PS, Shen LJ, et al: Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res 119(1–3):138–144, 2010 20299191
• Liao TV, Phan SV: Acute hyperglycemia associated with short-term use of atypical antipsychotic medications. Drugs 74(2):183–194, 2014 24399515
• Lieberman JA, First MB: Psychotic disorders. N Engl J Med 379(3):270–280, 2018
• Lieberman JA, Saltz BL, Johns CA, et al: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510, 1991 1675900
• Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR: Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev (1):CD001950, 2002 11869614
• Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K: Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Oct 18(4):CD001946, 2004 15495022
• Lindenmayer JP: Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat 6:261–267, 2010 20628628
• Lindström E, Lewander T, Malm U, et al: Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 55 (suppl 44):5–69, 2001 11860666
• Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100, 1987 2887090
• Lopez LV, Kane JM: Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res 147(2–3):368–374, 2013 23664462
• Lopez LV, Shaikh A, Merson J, et al: Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol 37(3):310–314, 2017 28353490
• López-Moríñigo JD, Ramos-Ríos R, David AS, Dutta R: Insight in schizophrenia and risk of suicide: a systematic update. Compr Psychiatry 53(4):313–322, 2012
• Lopez-Morinigo JD, Fernandes AC, Chang CK, et al: Suicide completion in secondary mental healthcare: a comparison study between schizophrenia spectrum disorders and all other diagnoses. BMC Psychiatry 14:213, 2014
• Lowe CM, Grube RR, Scates AC: Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 41(10):1700–1704, 2007 17785616
• Loxapac (loxapine hydrochloride) [product monograph]. Boucherville, QC, Canada, Sandoz Canada, July 2014
• Loxitane (loxapine) [prescribing information]. Corona, CA, Watson Pharma, February 2017
• Luciano A, Bond GR, Drake RE: Does employment alter the course and outcome of schizophrenia and other severe mental illnesses? A systematic review of longitudinal research. Schizophr Res 159(2–3):312–321, 2014 25278105
• Lucksted A, Medoff D, Burland J, et al: Sustained outcomes of a peer-taught family education program on mental illness. Acta Psychiatr Scand 127(4):279–286, 2013 22804103
• Lum A, Skelton E, Wynne O, Bonevski B: A systematic review of psychosocial barriers and facilitators to smoking cessation in people living with schizophrenia. Front Psychiatry 9:565, 2018 30459658
• MacEwan JP, Forma FM, Shafrin J, et al: Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm 22(11):1349–1361, 2016a 27783548
• MacEwan JP, Kamat SA, Duffy RA, et al: Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv 67(11):1183–1188, 2016b 27417897
• MacKinnon R, Michels R, Buckley P: The Psychiatric Interview in Clinical Practice, 3rd Edition. Arlington, VA, American Psychiatric Association Publishing, 2016
• Maeda K, Sugino H, Akazawa H, et al: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350(3):589–604, 2014 24947465
• Maher S, Cunningham A, O’Callaghan N, et al: Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol 6(3):178–184, 2016 27354906
• Mahmood S, Booker I, Huang J, Coleman CI: Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33(1):90–94, 2013 23277264
• Malla A, McGorry P: Early intervention in psychosis in young people: a population and public health perspective. Am J Public Health 109(S3):S181–S184, 2019 31242015
• Man WH, Colen-de Koning JC, Schulte PF, et al: The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol 37(2):155–161, 2017 28129312
• Mangurian C, Newcomer JW, Modlin C, Schillinger D: Diabetes and cardiovascular care among people with severe mental illness: a literature review. J Gen Intern Med 31(9):1083–1091, 2016 27149967
• Manu P, Dima L, Shulman M, et al: Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 132(2):97–108, 2015 26016380
• Manu P, Lapitskaya Y, Shaikh A, Nielsen J: Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther 25(2):e218–e223, 2018 29505490
• Mar PL, Raj SR: Orthostatic hypotension for the cardiologist. Curr Opin Cardiol 33(1):66–72, 2018 28984649
• Marcus SM, Medoff D, Fang LJ, et al: Generalizability in the Family-to-Family education program randomized waitlist-control trial. Psychiatr Serv 64(8):754–763, 2013 23633161
• Marino LA, Dixon LB: An update on supported employment for people with severe mental illness. Curr Opin Psychiatry 27(3):210–215, 2014 24613982
• Marques TR, Smith S, Bonaccorso S, et al: Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry 201:131–136, 2012 22700081
• Marshall M, Lockwood A: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev (2):CD001089, 2000 10796415
• Marshall M, Rathbone J: Early intervention for psychosis. Cochrane Database Syst Rev Jun 15(6):CD004718, 2011 21678345
• Marshall T, Goldberg RW, Braude L, et al: Supported employment: assessing the evidence. Psychiatr Serv 65(1):16–23, 2014 24247197
• Martin-Latry K, Goumy MP, Latry P, et al: Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 22(6):335–338, 2007 17513091
• Martino D, Karnik V, Osland S, et al: Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry 63(11):706743718777392, 2018 Epub ahead of print
• Mason M, Cates CJ, Smith I: Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev Jul 14(7):CD011090, 2015 26171909
• Matsuo M, Sano I, Ikeda Y, et al: Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs. Can J Ophthalmol 51(4):294–296, 2016 27521670
• Maust DT, Lin LA, Blow FC: Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv 70(2):97–106, 2019
• Mayoral F, Berrozpe A, de la Higuera J, et al: Efficacy of a family intervention program for prevention of hospitalization in patients with schizophrenia: a naturalistic multicenter controlled and randomized study in Spain. Rev Psiquiatr Salud Ment 8(2):83–91, 2015 25017624
• McCrary KJ, Weiden PJ, Gever MP: Schizophrenia: understanding your illness. Jacksonville, Florida Self-Directed Care Program District 4, 2019. Available at: www.floridasdc4.com/01_understanding.pdf. Accessed March 30, 2019.
• McCutcheon R, Beck K, D’Ambrosio E, et al: Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 137(1):39–46, 2018 29072776
• McDonagh MS, Dana T, Selph S, et al: Treatments for adults with schizophrenia: a systematic review [Comparative Effectiveness Review No 198, AHRQ Publ No 17(18)-EHC031-EF]. Rockville, MD, Agency for Healthcare Research and Quality, October 2017. Available at: https://effectivehealthcare.ahrq.gov/ topics/schizophrenia-adult/research-2017. Accessed May 10, 2019.
• McDonald-McGinn DM, Sullivan KE, Marino B, et al: 22q11.2 deletion syndrome. Nat Rev Dis Primers 1:15071, 2015 27189754
• McDowell C, Fossey E: Workplace accommodations for people with mental illness: a scoping review. J Occup Rehabil 25(1):197–206, 2015 24841728
• McEvoy JP: A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 48 (suppl):20–23, 1987 2887553
• McEvoy JP, McCue M, Freter S: Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. Clin Ther 9(4):429–433, 1987 2886223
• McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163(4):600–610, 2006 16585434
• McEvoy J, Gandhi SK, Rizio AA, et al: Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res 28(12):3303–3312, 2019
• McFarlane WR: Family interventions for schizophrenia and the psychoses: a review. Fam Process 55(3):460–482, 2016 27411376
• McGinty EE, Baller J, Azrin ST, et al: Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 42(1):96–124, 2016 26221050
• McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76, 2008
• McGurk SR, Twamley EW, Sitzer DI, et al: A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164(12):1791–1802, 2007 18056233
• McGurk SR, Mueser KT, Xie H, et al: Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry 172(9):852–861, 2015 25998278
• McGurk SR, Mueser KT, Xie H, et al: Cognitive remediation for vocational rehabilitation nonresponders. Schizophr Res 175(1–3):48–56, 2016 27209526
• McNiel DE, Eisner JP, Binder RL: The relationship between command hallucinations and violence. Psychiatr Serv 51(10):1288–1292, 2000 11013329
• Medalia A: Seven common questions about cognitive remediation. New York, Lieber Recovery Clinic, 2019. Available at: www.lieberclinic.com/cognitive-remediation. Accessed April 12, 2019.
• Medalia A, Herlands T, Saperstein A, Revheim N: Cognitive Remediation for Psychological Disorders: Therapist Guide (Treatments That Work), 2nd Edition. New York, Oxford University Press, 2018
• Medalia A, Erlich MD, Soumet-Leman C, Saperstein AM: Translating cognitive behavioral interventions from bench to bedside: the feasibility and acceptability of cognitive remediation in research as compared to clinical settings. Schizophr Res 203:49–54, 2019 28768601
• Mehta SH, Morgan JC, Sethi KD: Drug-induced movement disorders. Neurol Clin 33(1):153–174, 2015 25432728
• Meldrum ML, Kelly EL, Calderon R, et al: Implementation status of assisted outpatient treatment programs: a national survey. Psychiatr Serv 67(6):630–635, 2016 26828396
• Melkote R, Singh A, Vermeulen A, et al: Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Res 201:324–328, 2018 29804929
• Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60(1):82–91, 2003 12511175
• Melzer-Ribeiro DL, Rigonatti SP, Kayo M, et al: Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT–sham controlled trial. Archives of Clinical Psychiatry (São Paulo) 44(2):45–50, 2017
• Mental Health America: Mental Health America. Alexandria, VA, Mental Health America, 2019. Available at: www.mhanational.org. Accessed September 29, 2019.
• Mentzel TQ, Lieverse R, Bloemen O, et al; Genetic Risk and Outcome of Psychosis (GROUP) Investigators: High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol 37(2):231–238, 2017 28141621
• Mentzel TQ, van der Snoek R, Lieverse R, et al: Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry 79(6):17r11852, 2018
• Metcalfe JD, Drake RE, Bond GR: Economic, labor, and regulatory moderators of the effect of individual placement and support among people with severe mental illness: a systematic review and meta-analysis. Schizophr Bull 44(1):22–31, 2018 29036727
• Metzner JL: Class action litigation in correctional psychiatry. J Am Acad Psychiatry Law 30(1):19–29, discussion 30–32, 2002
• Metzner JL: Mental health considerations for segregated inmates, in Standards for Health Services in Prisons. Chicago, IL, National Commission on Correctional Healthcare, 2003, pp 241–254
• Metzner JL, Fellner J: Solitary confinement and mental illness in U.S. prisons: a challenge for medical ethics. J Am Acad Psychiatry Law 38(1):104–108, 2010 20305083
• Meyer JM: Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr 18 (suppl 1):58–67, quiz 68, 2013
• Meyer JM: Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr 22(S1):14–28, 2017 29350127
• Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70(1):1–17, 2004 15246458
• MGH Center for Women’s Mental Health: National pregnancy registry for atypical antipsychotics. Boston, MA, MGH Center for Women’s Mental Health, 2019. Available at: https://womensmentalhealth.org/research/pregnancyregistry/atypicalantipsychotic. Accessed September 21, 2019.
• Michl J, Scharinger C, Zauner M, et al: A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. Eur Neuropsychopharmacol 24(9):1463–1474, 2014 25044049
• Micromedex: IBM Micromedex® Web Applications Access. Greenwood Village, CO, IBM Watson Health, 2019. Available at: www.micromedexsolutions.com. Accessed January 4, 2019.
• Miller DD, McEvoy JP, Davis SM, et al: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80(1):33–43, 2005 16171976
• Miller DD, Caroff SN, Davis SM, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193(4):279–288, 2008 18827289
• Miller DT, Adam MP, Aradhya S, et al: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86(5):749–764, 2010 20466091
• Mindham RH, Gaind R, Anstee BH, Rimmer L: Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced parkinsonism. Psychol Med 2(4):406–413, 1972 4571143
• Mintz AR, Dobson KS, Romney DM: Insight in schizophrenia: a meta-analysis. Schizophr Res 61(1):75–88, 2003 12648738
• Misiak B, Stanczykiewicz B, Laczmanski L, Frydecka D: Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis. Schizophr Res 190:18–27, 2017 28325572
• Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42(1):125–147, 2012 21846426
• Mitchell AJ, Vancampfort D, De Herdt A, et al: Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 39(2):295–305, 2013a 22927670
• Mitchell AJ, Vancampfort D, Sweers K, et al: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. Schizophr Bull 39(2):306–318, 2013b 22207632
• Mizuno Y, Suzuki T, Nakagawa A, et al: Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40(6):1385–1403, 2014 24636967
• Moban (molindone) [prescribing information]. Malvern, PA, Endo Pharmaceuticals, February 2017
• Moberg PJ, Richman MJ, Roalf DR, et al: Neurocognitive functioning in patients with 22q11.2 deletion syndrome: a meta-analytic review. Behav Genet 48(4):259–270, 2018 29922984
• Modini M, Tan L, Brinchmann B, et al: Supported employment for people with severe mental illness: systematic review and meta-analysis of the international evidence. Br J Psychiatry 209(1):14–22, 2016 27103678
• Mohamed S, Rosenheck R, McEvoy J, et al: Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35(2):336–346, 2009 18586692
• Molindone hydrochloride tablets [prescribing information]. Middlesex, NJ, CorePharma, August 2014
• Molindone hydrochloride tablets [prescribing information]. Laurelton, NY, Epic Pharma, April 2018
• Moncrieff J, Steingard S: A critical analysis of recent data on the long-term outcome of antipsychotic treatment. Psychol Med 49(5):750–753, 2019 30563582
• Monroe-DeVita M, Morse G, Bond GR: Program fidelity and beyond: multiple strategies and criteria for ensuring quality of assertive community treatment. Psychiatr Serv 63(8):743–750, 2012 22508406
• Monuteaux MC, Lee LK, Hemenway D, et al: Firearm ownership and violent crime in the U.S.: an ecologic study. Am J Prev Med 49(2):207–214, 2015 26091930
• Moons T, de Roo M, Claes S, Dom G: Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12(8):1193–1211, 2011 21843066
• Moore S, Shiers D, Daly B, et al: Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 132(2):109–121, 2015 25958971
• Moreno-Küstner B, Martín C, Pastor L: Prevalence of psychotic disorders and its association with methodological issues: a systematic review and meta-analyses. PLoS One 13(4):e0195687, 2018 29649252
• Morgan VA, Morgan F, Galletly C, et al: Sociodemographic, clinical and childhood correlates of adult violent victimisation in a large, national survey sample of people with psychotic disorders. Soc Psychiatry Psychiatr Epidemiol 51(2):269–279, 2016 26581211
• Moriarty DG, Zack MM, Kobau R: The Centers for Disease Control and Prevention’s Healthy Days Measures: population tracking of perceived physical and mental health over time. Health Qual Life Outcomes 1:37, 2003
• Morosini PL, Magliano L, Brambilla L, et al: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101(4):323–329, 2000 10782554
• Morrato EH, Newcomer JW, Kamat S, et al: Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32(6):1037–1042, 2009 19244091
• Morrison AP: A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis: learning from clinical trials. Psychosis 9(3):271–281, 2017
• Morrison AP, Pyle M, Gumley A, et al; FOCUS trial group: Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. Lancet Psychiatry 5(8):633–643, 2018 30001930
• Morrissey JP, Domino ME, Cuddeback GS: Expedited Medicaid enrollment, mental health service use, and criminal recidivism among released prisoners with severe mental illness. Psychiatr Serv 67(8):842–849, 2016 26975522
• Morse G, Glass AM, Monroe-DeVita M: ACT and recovery: what we know about their compatibility. Adm Policy Ment Health 43(2):219–230, 2016 25638223
• Mościcki EK, Clarke DE, Kuramoto SJ, et al: Testing DSM-5 in routine clinical practice settings: feasibility and clinical utility. Psychiatr Serv 64(10):952–960, 2013 23852272
• Mosheva M, Korotkin L, Gur RE, et al: Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review. Eur Child Adolesc Psychiatry Apr 4, 2019 Epub ahead of print
• Mountjoy CQ, Baldacchino AM, Stubbs JH: British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 156(1):158–159, 1999
• Mueller DR, Schmidt SJ, Roder V: One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients. Schizophr Bull 41(3):604–616, 2015 25713462
• Mueser KT, Corrigan PW, Hilton DW, et al: Illness management and recovery: a review of the research. Psychiatr Serv 53(10):1272–1284, 2002 12364675
• Mueser KT, Clark RE, Haines M, et al: The Hartford study of supported employment for persons with severe mental illness. J Consult Clin Psychol 72(3):479–490, 2004 15279531
• Mueser KT, Pratt SI, Bartels SJ, et al: Randomized trial of social rehabilitation and integrated health care for older people with severe mental illness. J Consult Clin Psychol 78(4):561–573, 2010 20658812
• Mueser KT, Deavers F, Penn DL, Cassisi JE: Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol 9:465–497, 2013 23330939
• Mueser KT, Penn DL, Addington J, et al: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatr Serv 66(7):680–690, 2015 25772766
• Mukundan A, Faulkner G, Cohn T, Remington G: Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev Dec 8(12):CD006629, 2010 21154372
• Munetz MR, Benjamin S: How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 39(11):1172–1177, 1988
• Muralidharan A, Brown CH, ,Peer JE, et al: Living Well: an intervention to improve medical illness self- management among individuals with serious mental illness. Psychiatr Serv 70(1):19–25, 2019 30353790
• Murray H, Wortzel HS: Psychiatric advance directives: origins, benefits, challenges, and future directions. J Psychiatr Pract 25(4):303–307, 2019 31291211
• Myles H, Myles N, Antic NA, et al: Obstructive sleep apnea and schizophrenia: a systematic review to inform clinical practice. Schizophr Res 170(1):222–225, 2016
• Myles N, Newall HD, Curtis J, et al: Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry 73(4):468–475, 2012
• Myles N, Myles H, Clark SR, et al: Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: a systematic review of the literature and clinical recommendations. Aust N Z J Psychiatry 51(10):980–989, 2017 28747065
• Myles N, Myles H, Xia S, et al: Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 138(2):101–109, 2018 29786829
• Myles N, Myles H, Xia S, et al: A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry 53(5):403–412, 2019 30864459
• Naber D, Leppig M, Grohmann R, Hippius H: Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia: a retrospective study of 387 patients. Psychopharmacology (Berl) 99(suppl):S73–S76, 1989 2813668
• Narrow WE, Clarke DE, Kuramoto SJ, et al: DSM-5 field trials in the United States and Canada, part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5. Am J Psychiatry 170(1):71–82, 2013
• Naslund JA, Aschbrenner KA, Scherer EA, et al: Lifestyle intervention for people with severe obesity and serious mental illness. Am J Prev Med 50(2):145–153, 2016 26385164
• Nasrallah HA, Tandon R: Classic antipsychotic medications, in The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5th Edition. Edited by Schatzberg AF, Nemeroff CB. Arlington, VA, American Psychiatric Association Publishing, 2017, pp 603–621
• Nasser AF, Henderson DC, Fava M, et al: Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia. J Clin Psychopharmacol 36(2):130–140, 2016 26862829
• National Alliance on Mental Illness: NAMI Family & Friends. Arlington, VA, National Alliance on Mental Illness, 2019a. Available at: www.nami.org/find-support/nami-programs/nami-family-friends. Accessed September 29, 2019.
• National Alliance on Mental Illness: NAMI Family-to-Family. Arlington, VA, National Alliance on Mental Illness, 2019b. Available at: www.nami.org/Find-Support/NAMI-Programs/NAMI-Family-to-Family. Accessed April 11, 2019.
• National Cancer Institute: Quit smoking. Bethesda, MD, National Cancer Institute, 2019. Available at: https://smokefree.gov/quit-smoking. Accessed December 31, 2018.
• National Commission on Correctional Health Care: Position statement: solitary confinement (isolation). J Correct Health Care 22(3):257–263, 2016 27302711
• National Institute for Health and Care Excellence: Psychosis and schizophrenia in adults: prevention and management: updated edition 2014. London, National Collaborating Centre for Mental Health, 2014. Available at: www.nice.org.uk/guidance/cg178. Accessed May 7, 2019.
• National Institute of Mental Health: What is RAISE? Bethesda, MD, National Institute of Mental Health, 2019a. Available at: www.nimh.nih.gov/health/topics/schizophrenia/raise/what-is-raise.shtml. Accessed October 1, 2019.
• National Institute of Mental Health: Recovery After an Initial Schizophrenia Episode (RAISE): State Health Administrators and Clinics. Bethesda, MD, National Institute of Mental Health, 2019b. Available at: www.nimh.nih.gov/health/topics/schizophrenia/raise/state-health-administrators-and-clinics.shtml. Accessed on March 31, 2019.
• Navane (thiothixene) [prescribing information]. New York, Pfizer, December 2010
• NAVIGATE: NAVIGATE. Philadelphia, PA, NAVIGATE, 2019. Available at: http://navigateconsultants.org/manuals. Accessed May 6, 2020.
• Nesvåg R, Knudsen GP, Bakken IJ, et al: Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol 50(8):1267–1276, 2015 25680837
• Newcomer JW, Weiden PJ, Buchanan RW: Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 74(11):1108–1120, 2013 24330898
• Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthøj C: Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychol Med 47(9):1668–1677, 2017 28166863
• Niskanen P, Achté K, Jaskari M, et al: Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiatria Fennica 307–313, 1974
• Nordentoft M, Jeppesen P, Abel M, et al: OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 43:s98–s106, 2002 12271808
• Nordentoft M, Mortensen PB, Pedersen CB: Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 68(10):1058–1064, 2011 21969462
• Norman R, Lecomte T, Addington D, Anderson E: Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults. Can J Psychiatry 62(9):617–623, 2017
• Novalis PN, Rojcewicz SJ, Peele R: Clinical Manual of Supportive Psychotherapy. Washington, DC, American Psychiatric Press, 1993, p 384
• Nuplazid (10 and 34 mg pimavanserin) [prescribing information]. San Diego, CA, Acadia Pharmaceuticals, June 2018
• Nuplazid (17 mg pimavanserin) [prescribing information]. San Diego, CA, Acadia Pharmaceuticals, June 2018
• Oakley P, Kisely S, Baxter A, et al: Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 102:245–253, 2018 29723811
• O’Brien A: Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry 31(7):683–693, 2016 26679687
• O’Brien CF, Jimenez R, Hauser RA, et al: NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 30(12):1681–1687, 2015 26346941
• Office for Civil Rights: Health information privacy: information related to mental and behavioral health, including opioid overdose. Washington, DC, U.S. Department of Health and Human Services, December 19, 2017a. Available at: www.hhs.gov/hipaa/for-professionals/special-topics/mental-health/index.html. Accessed November 18, 2018.
• Office for Civil Rights: HIPAA privacy rule and sharing information related to mental health. Washington, DC, U.S. Department of Health and Human Services, December 19, 2017b. Available at: www.hhs.gov/sites/default/files/hipaa-privacy-rule-and-sharing-info-related-to-mental-health.pdf. Accessed November 18, 2018.
• O’Keefe ML, Klebe KJ, Metzner J, et al: A longitudinal study of administrative segregation. J Am Acad Psychiatry Law 41(1):49–60, 2013 23503176
• Olbert CM, Nagendra A, Buck B: Meta-analysis of black vs. white racial disparity in schizophrenia diagnosis in the United States: do structured assessments attenuate racial disparities? J Abnorm Psychol 127(1):104–115, 2018 29094963
• Olfson M, Gerhard T, Huang C, et al: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72(12):1172–1181, 2015 26509694
• Olfson M, Gerhard T, Crystal S, Stroup TS: Clozapine for schizophrenia: state variation in evidence-based practice. Psychiatr Serv 67(2):152, 2016 26522679
• Olten B, Bloch MH: Meta regression: relationship between antipsychotic receptor binding profiles and side-effects. Prog Neuropsychopharmacol Biol Psychiatry 84 (Pt A):272–281, 2018 29410000
• Oluwoye O, Monroe-DeVita M, Burduli E, et al: Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: data from the national RAISE-ETP study. Early Interv Psychiatry 13(1):142–146, 2018
• Ondo WG, Hanna PA, Jankovic J: Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 156(8):1279–1281, 1999 10450276
• OnTrackNY: Resources. New York, OnTrackNY, 2019. Available at: https://ontrackny.org/Resources. Accessed March 31, 2019.
• Opler MGA, Yavorsky C, Daniel DG: Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions. Innov Clin Neurosci 14(11–12):77–81, 2017 29410941
• Opoka SM, Lincoln TM: The effect of cognitive behavioral interventions on depression and anxiety symptoms in patients with schizophrenia spectrum disorders: a systematic review. Psychiatr Clin North Am 40(4):641–659, 2017 29080591
• Orap (pimozide) [prescribing information]. Sellersville, PA, Teva Pharmaceuticals, March 2014
• Orap (pimozide) [prescribing information]. Horsham, PA, Teva Select Brands, April 2018
• Orap (pimozide) [product monograph]. Vaughan, ON, Canada, AA Pharma, February 2019
• Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, et al: Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev Jun 28 6(6):CD009005, 2017 28658515
• Østergaard MLD, Nordentoft M, Hjorthøj C: Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction 112(7):1250–1259, 2017 28192643
• Østergaard SD, Foldager L, Mors O, et al: The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Bull 44(2):453–462, 2018a 28575321
• Østergaard SD, Foldager L, Mors O, et al: The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand 138(5):420–431, 2018b 30168131
• Ostuzzi G, Bighelli I, So R, et al: Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res 183:10–21, 2017 27866695
• Ouzzine M, Gulberti S, Ramalanjaona N, et al: The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication. Front Cell Neurosci 8:349, 2014 25389387
• Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812, 1962
• Ozbilen M, Adams CE: Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol 29(2):141–146, 2009 19512975
• Pakzad-Vaezi KL, Etminan M, Mikelberg FS: The association between cataract surgery and atypical antipsychotic use: a nested case-control study. Am J Ophthalmol 156(6):1141–1146.e1, 2013 24075430
• Palmer BA, Pankratz VS, Bostwick JM: The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62(3):247–253, 2005 15753237
• Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M: Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 69(5):759–768, 2008 18452342
• Palmier-Claus JE, Ainsworth J, Machin M, et al: The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry 12:172, 2012
• Pappa S, Tsouli S, Apostolou G, et al: Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33(6):271–275, 2010 21121175
• Paschen S, Deuschl G: Patient evaluation and selection for movement disorders surgery: the changing spectrum of indications. Prog Neurol Surg 33:80–93, 2018 29332075
• Patel MM, Brown JD, Croake S, et al: The current state of behavioral health quality measures: where are the gaps? Psychiatr Serv 66(8):865–871, 2015 [Abstract]
• Patel MX, De Zoysa N, Bernadt M, David A: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 23(7):789–796, 2009 18583438
• Patel MX, de Zoysa N, Bernadt M, et al: Are depot antipsychotics more coercive than tablets? The patient’s perspective. J Psychopharmacol 24(10):1483–1489, 2010a 19304865
• Patel MX, Haddad PM, Chaudhry IB, et al: Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 24(10):1473–1482, 2010b 19477883
• Patterson-Lomba O, Ayyagari R, Carroll B: Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol 19(1):174, 2019 31325958
• PDSP: PDSP Ki database: Chapel Hill, NC, PDSP, 2019. Available at: https://pdsp.unc.edu/databases/kidb.php. Accessed January 16, 2019.
• Pearsall R, Smith DJ, Pelosi A, Geddes J: Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis. BMC Psychiatry 14:117, 2014 24751159
• Pekkala E, Merinder L: Psychoeducation for schizophrenia. Cochrane Database Syst Rev (2):CD002831, 2002
• Pelzer AC, van der Heijden FM, den Boer E: Systematic review of catatonia treatment. Neuropsychiatr Dis Treat 14:317–326, 2018 29398916
• Pendopharm: ^Prpdp-benztropine prescribing information. Montreal, QC, Canada, Pendopharm, February 2, 2015. Available at: https://pdf.hres.ca/dpd_pm/00029138.PDF. Accessed April 22, 2019.
• Pentaraki A, Utoblo B, Kokkoli EM: Cognitive remediation therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev (11):CD012865, 2017
• Penttilä M, Jääskeläinen E, Hirvonen N, et al: Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205(2):88–94, 2014
• Perphenazine [prescribing information]. Atlanta, GA, Wilshire Pharmaceuticals, November 2016
• Perphenazine [prescribing information]. Morgantown, WV, Mylan Pharmaceuticals, March 2017
• Perry BI, McIntosh G, Weich S, et al: The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry 3(11):1049–1058, 2016 27720402
• Perry LA, Ramson D, Stricklin S: Mirtazapine adjunct for people with schizophrenia. Cochrane Database Syst Rev May 26 5(5):CD011943, 2018 29802811
• Perseris (risperidone) [prescribing information]. North Chesterfield, VA, Indivior, July 2018
• Petrides G, Malur C, Braga RJ, et al: Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 172(1):52–58, 2015 25157964
• Pharoah F, Mari J, Rathbone J, Wong W: Family intervention for schizophrenia. Cochrane Database Syst Rev Dec 8(12):CD000088, 2010 21154340
• Phillips IR, Shephard EA: Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol 13(2):167–181, 2017 27678284
• Pileggi DJ, Cook AM: Neuroleptic malignant syndrome. Ann Pharmacother 50(11):973–981, 2016 27423483
• Pillinger T, Beck K, Gobjila C, et al: Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261–269, 2017a 28097367
• Pillinger T, Beck K, Stubbs B, Howes OD: Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry 211(6):339–349, 2017b 28982658
• Pincus HA, Scholle SH, Spaeth-Rublee B, et al: Quality measures for mental health and substance use: gaps, opportunities, and challenges. Health Aff (Millwood) 35(6):1000–1008, 2016
• Pinninti NR, Faden J, Adityanjee A: Are second-generation antipsychotics useful in tardive dystonia? Clin Neuropharmacol 38(5):183–197, 2015 26366970
• Pisani F, Oteri G, Costa C, et al: Effects of psychotropic drugs on seizure threshold. Drug Saf 25(2):91–110, 2002 11888352
• Pisciotta AV: Agranulocytosis induced by certain phenothiazine derivatives. JAMA 208(10):1862–1868, 1969 4890332
• Plana-Ripoll O, Pedersen CB, Holtz Y, et al: Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry 76(3):259–270, 2019
• Poewe W, Djamshidian-Tehrani A: Movement disorders in systemic diseases. Neurol Clin 33(1):269–297, 2015 25432733
• Polcwiartek C, Vang T, Bruhn CH, et al: Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology (Berl) 233(21–22):3663–3672, 2016 27592232
• Pompili M, Amador XF, Girardi P, et al: Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 6:10, 2007
• Pompili M, Lester D, Dominici G, et al: Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res 146(1-3):1–9, 2013 23499244
• Popovic D, Benabarre A, Crespo JM, et al: Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psychiatr Scand 130(6):418–426, 2014 25230813
• Pottegård A, Lash TL, Cronin-Fenton D, et al: Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. Br J Clin Pharmacol 84(9):2152–2161, 2018 29858518
• Poyurovsky M, Weizman A: Very low-dose mirtazapine (7.5 mg) in treatment of acute antipsychotic-associated akathisia. J Clin Psychopharmacol 38(6):609–611, 2018 30300293
• Praharaj SK, Kongasseri S, Behere RV, Sharma PS: Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 5(5):307–313, 2015 26557987
• Predmore Z, Mattke S, Horvitz-Lennon M: Potential benefits to patients and payers from increased measurement of antipsychotic plasma levels in the management of schizophrenia. Psychiatr Serv 69(1):12–14, 2018 29191139
• Preskorn S, Flynn A, Macaluso M: Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and/or dystonia in patients with major depressive disorder, part 1. J Psychiatr Pract 21(5):359–369, 2015 26348804
• Pringsheim T, Kelly M, Urness D, et al: Physical health and drug safety in individuals with schizophrenia. Can J Psychiatry 62(9):673–683, 2017
• Pringsheim T, Gardner D, Addington D, et al: The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry Jan 1:706743718760288, 2018 Epub ahead of print
• Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ (eds): Clinical Handbook of Psychotropic Drugs, 23rd Edition. Boston, MA, Göttingen Hogrefe, 2019. Available at: https://chpd.hogrefe.com. Accessed January 4, 2019.
• Pugh RN, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649, 1973 4541913
• Pui-yin Chung J, Shiu-yin Chong C, Lai-wah Dunn E, et al: The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 53(12):857–862, 2008 19087484
• Pyne JM, Fischer EP, Gilmore L, et al: Development of a patient-centered antipsychotic medication adherence intervention. Health Educ Behav 41(3):315–324, 2014 24369177
• Quetiapine (Seroquel) and QT-interval prolongation. Med Lett Drugs Ther 53(1374):79–80, 2011 21959358
• Rabinowitz J, Levine SZ, Garibaldi G, et al: Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 137(1–3):147–150, 2012
• Ranasinghe I, Sin J: A systematic review of evidence-based treatment for individuals with treatment-resistant schizophrenia and a suboptimal response to clozapine monotherapy. Psychosis 6(3):253–265, 2014
• Randall JR, Walld R, Finlayson G, et al: Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatry 59(10):531–538, 2014 25565686
• Ratey JJ, Leveroni C, Kilmer D, et al: The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 54(6):219–223, 1993 8331090
• Rathbone J, Soares-Weiser K: Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Oct 18(4):CD003727, 2006 17054182
• Rautaharju PM, Surawicz B, Gettes LS, et al; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society: AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram, part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 53(11):982–991, 2009 19281931
• Reagu S, Jones R, Kumari V, Taylor PJ: Angry affect and violence in the context of a psychotic illness: a systematic review and meta-analysis of the literature. Schizophr Res 146(1–3):46–52, 2013
• Rebok GW, Ball K, Guey LT, et al; ACTIVE Study Group: Ten-year effects of the Advanced Cognitive Training for Independent and Vital Elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc 62(1):16–24, 2014 24417410
• Reeder C, Pile V, Crawford P, et al: The feasibility and acceptability to service users of CIRCuiTS, a computerized cognitive remediation therapy programme for schizophrenia. Behav Cogn Psychother 44(3):288–305, 2016 26004421
• Reeder C, Huddy V, Cella M, et al: A new generation computerised metacognitive cognitive remediation programme for schizophrenia (CIRCuiTS): a randomised controlled trial. Psychol Med 1–11, 2017 28866988
• Register-Brown K, Hong LE: Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis. Schizophr Res 160(1–3):20–26, 2014
• Reingle Gonzalez JM, Connell NM: Mental health of prisoners: identifying barriers to mental health treatment and medication continuity. Am J Public Health 104(12):2328–2333, 2014 25322306
• Relling MV, Klein TE: CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 89(3):464–467, 2011 21270786
• Remington G, Agid O, Foussias G, et al: Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 225(3):505–518, 2013 23179967
• Remington G, Addington D, Honer W, et al: Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 62(9):604–616, 2017 28703015
• Reser MP, Slikboer R, Rossell SL: A systematic review of factors that influence the efficacy of cognitive remediation therapy in schizophrenia. Aust N Z J Psychiatry 53(7):624–641, 2019 31177813
• Revell ER, Neill JC, Harte M, et al: A systematic review and meta-analysis of cognitive remediation in early schizophrenia. Schizophr Res 168(1–2):213–222, 2015 26305063
• Rexulti (brexpiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, May 2019
• Reynolds RJ, Day SM, Shafer A, Becker E: Mortality rates and excess death rates for the seriously mentally ill. J Insur Med 47(4):212–219, 2018 30653378
• Rezansoff SN, Moniruzzaman A, Fazel S, et al: Housing first improves adherence to antipsychotic medication among formerly homeless adults with schizophrenia: results of a randomized controlled trial. Schizophr Bull 43(4):852–861, 2017 27665002
• Richter D, Hoffmann H: Effectiveness of supported employment in non-trial routine implementation: systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 54(5):525–531, 2019
• Risperdal Consta (risperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, January 2019
• Risperdal (risperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, January 2019
• Risperidone orally disintegrating tablets (risperidone) [prescribing information]. Princeton, NJ, Sandoz, February 2019
• Roché MW, Boyle DJ, Cheng CC, et al: Prevalence and risk of violent ideation and behavior in serious mental illnesses: an analysis of 63,572 patient records. J Interpers Violence Mar 1: 886260518759976, 2018 Epub ahead of print
• Røge R, Møller BK, Andersen CR, et al: Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140(1–3):204–213, 2012 22831769
• Rogers HL, Bhattaram A, Zineh I, et al: CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration’s new dosing recommendations. J Clin Psychiatry 73(9):1187–1190, 2012 23059146
• Rohde C, Polcwiartek C, Kragholm K, et al: Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatr Scand 137(1):47–53, 2018 29064084
• Ronaldson KJ, Fitzgerald PB, McNeil JJ: Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 132(4):231–240, 2015 25865238
• Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 146(6):717–725, 1989 2567121
• Rosenheck RA, Davis S, Covell N, et al: Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial. Schizophr Res 107(1):22–29, 2009 18993031
• Rostack J: FDA to require diabetes warning on antipsychotics. Psychiatric News 30(20), Oct 17, 2003
• Roth BL, Kroeze WK, Patel WK, Lopez E: The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrasment of riches? Neuroscientist 6(4):252–262, 2000
• Rothe PH, Heres S, Leucht S: Dose equivalents for second generation long-acting injectable antipsychotics: the minimum effective dose method. Schizophr Res 193:23–28, 2018 28735640
• Rouillon F, Eriksson L, Burba B, et al: Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Acta Neuropsychiatr 25(5):297–306, 2013 25287730
• Rowland A, Miners JO, Mackenzie PI: The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45(6):1121–1132, 2013 23500526
• Roy L, Crocker AG, Nicholls TL, et al: Criminal behavior and victimization among homeless individuals with severe mental illness: a systematic review. Psychiatr Serv 65(6):739–750, 2014 24535245
• Rubio-Abadal E, Del Cacho N, Saenz-Navarrete G, et al; PROLACT Group: How hyperprolactinemia affects sexual function in patients under antipsychotic treatment. J Clin Psychopharmacol 36(5):422–428, 2016 27433851
• Rush AJ, First MB, Blacker D (eds): Handbook of Psychiatric Measures, 2nd Edition. Washington, DC, American Psychiatric Publishing, 2008
• Sachdev P, Mason C, Hadzi-Pavlovic D: Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 154(8):1156–1158, 1997 9247408
• Sachs HC; Committee on Drugs: The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 132(3):e796–e809, 2013 23979084
• Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64(10):1123–1131, 2007
• Saklad SR: Paliperidone palmitate: adjusting dosing intervals and measuring serum concentrations. Curr Psychiatr 17(8):45–47, 55, 2018
• Saks ER: Some thoughts on denial of mental illness. Am J Psychiatry 166(9):972–973, 2009 19723794
• Salahudeen MS, Duffull SB, Nishtala PS: Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 15:31, 2015 25879993
• Saltz BL, Woerner MG, Kane JM, et al: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266(17):2402–2406, 1991 1681122
• Samara M, Leucht S: Clozapine in treatment-resistant schizophrenia. Br J Psychiatry 210(4):299, 2017 28373226
• Samara MT, Leucht C, Leeflang MM, et al: Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172(7):617–629, 2015 26046338
• Samara MT, Dold M, Gianatsi M, et al: Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73(3):199–210, 2016 26842482
• Samara MT, Klupp E, Helfer B, et al: Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database Syst Rev May 11 5(5):CD0011883, 2018 29750432
• SAMHSA-HRSA Center of Excellence for Integrated Health Solutions: Tobacco cessation. Rockville, MD, SAMHSA-HRSA Center for Integrated Health Solutions, 2018. Available at: www.integration.samhsa.gov/health-wellness/wellness-strategies/tobacco-cessation-2. Accessed December 31, 2018.
• SAMHSA-HRSA Center of Excellence for Integrated Health Solutions: SBIRT: Screening, brief intervention, and referral to treatment. Rockville, MD, SAMHSA-HRSA Center for Integrated Health Solutions, 2019. Available at: www.integration.samhsa.gov/clinical-practice/sbirt. Accessed September 22, 2019.
• Santesteban-Echarri O, Paino M, Rice S, et al: Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev 58:59–75, 2017 29042139
• Saperstein AM, Medalia A: The empirical basis for the practice of cognitive remediation for schizophrenia. Neuropsychiatry (London) 2(2):101–109, 2012
• Saphris (asenapine) [prescribing information]. Irvine, CA, Allergan USA, February 2017
• Sara GE, Burgess PM, Malhi GS, et al: Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry 48(11):1036–1047, 2014 24819935
• Sariaslan A, Lichtenstein P, Larsson H, Fazel S: Triggers for violent criminality in patients with psychotic disorders. JAMA Psychiatry 73(8):796–803, 2016 27410165
• Satterthwaite TD, Wolf DH, Rosenheck RA, et al: A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 69(12):1869–1879, 2008 19192477
• Schalinski I, Breinlinger S, Hirt V, et al: Environmental adversities and psychotic symptoms: the impact of timing of trauma, abuse, and neglect. Schizophr Res 205:4–9, 2019
• Scherf-Clavel M, Samanski L, Hommers LG, et al: Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Int Clin Psychopharmacol 34(2):93–100, 2019
• Schneider M, Regente J, Greiner T, et al: Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015. Eur Arch Psychiatry Clin Neurosci Nov 30, 2018 Epub ahead of print
• Schoenbaum M, Sutherland JM, Chappel A, et al: Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull 43(6):1262–1272, 2017 28398566
• Schwartz RC, Blankenship DM: Racial disparities in psychotic disorder diagnosis: a review of empirical literature. World J Psychiatry 4(4):133–140, 2014 25540728
• Scott D, Platania-Phung C, Happell B: Quality of care for cardiovascular disease and diabetes amongst individuals with serious mental illness and those using antipsychotic medications. J Healthc Qual 34(5):15–21, 2012 22092725
• Scottish Intercollegiate Guidelines Network (SIGN): Management of schizophrenia. Edinburgh, SIGN, May 2013. Available at: www.sign.ac.uk/assets/sign131.pdf. Accessed April 26, 2019.
• Secher RG, Hjorthøj CR, Austin SF, et al: Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis. Schizophr Bull 41(3):617–626, 2015 25381449
• Segal SP, Hayes SL, Rimes L: The utility of outpatient commitment I: a need for treatment and a least restrictive alternative to psychiatric hospitalization. Psychiatr Serv 68(12):1247–1254, 2017a Epub Aug 1 2017 28760100
• Segal SP, Hayes SL, Rimes L: The utility of outpatient commitment II: mortality risk and protecting health, safety, and quality of life. Psychiatr Serv 68(12):1255–1261, 2017b 28760099
• Sellwood W, Barrowclough C, Tarrier N, et al: Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. Acta Psychiatr Scand 104(5):346–355, 2001 11722315
• Sellwood W, Wittkowski A, Tarrier N, Barrowclough C: Needs-based cognitive-behavioural family intervention for patients suffering from schizophrenia: 5-year follow-up of a randomized controlled effectiveness trial. Acta Psychiatr Scand 116(6):447–452, 2007 17961200
• Semenza DC, Grosholz JM: Mental and physical health in prison: how co-occurring conditions influence inmate misconduct. Health Justice 7(1):1, 2019 30612284
• Seroquel (quetiapine) [prescribing information]. Wilmington, DE, AstraZeneca Pharmaceuticals, August 2019
• Seroquel XR (quetiapine) [prescribing information]. Wilmington, DE, AstraZeneca Pharmaceuticals, August 2019
• Serretti A, Chiesa A: A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 26(3):130–140, 2011 21191308
• Shafrin J, Schwartz TT, Lakdawalla DN, Forma FM: Estimating the value of new technologies that provide more accurate drug adherence information to providers for their patients with schizophrenia. J Manag Care Spec Pharm 22(11):1285–1291, 2016 27783545
• Sharma R, Alla K, Pfeffer D, et al: An appraisal of practice guidelines for smoking cessation in people with severe mental illness. Aust N Z J Psychiatry 51(11):1106–1120, 2017 28859486
• Shen V, Clarence-Smith K, Hunter C, Jankovic J: Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (N Y) 3:tre-03-191-4337-1, 2013 24255799
• Shen WK, Sheldon RS, Benditt DG, et al: 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 70(5):e39–e110, 2017 28286221
• Sherman LJ, Lynch SE, Teich J, Hudock WJ: Availability of supported employment in specialty mental health treatment facilities and facility characteristics: 2014. The CBHSQ Report. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2017 28749638
• Shields LS, Pathare S, van der Ham AJ, Bunders J: A review of barriers to using psychiatric advance directives in clinical practice. Adm Policy Ment Health 41(6):753–766, 2014 24248818
• Short T, Thomas S, Mullen P, Ogloff JR: Comparing violence in schizophrenia patients with and without comorbid substance-use disorders to community controls. Acta Psychiatr Scand 128(4):306–313, 2013
• Siegel M, Rothman EF: Firearm ownership and suicide rates among US men and women, 1981–2013. Am J Public Health 106(7):1316–1322, 2016 27196643
• Silberstein J, Harvey PD: Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes. Cogn Neuropsychiatry 24(1):28–39, 2019 30477401
• Silver H, Geraisy N, Schwartz M: No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 56(4):167–170, 1995 7713856
• Sin J, Gillard S, Spain D, et al: Effectiveness of psychoeducational interventions for family carers of people with psychosis: a systematic review and meta-analysis. Clin Psychol Rev 56:13–24, 2017a 28578249
• Sin J, Spain D, Furuta M, et al: Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness. Cochrane Database Syst Rev Jan 24 1(1):CD011464, 2017b 28116752
• Sinclair D, Adams CE: Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 14:253, 2014 25227719
• Sinclair DJ, Zhao S, Qi F, et al: Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev Mar 19 3(3):CD011847, 2019 30888709
• Singh JP, Grann M, Lichtenstein P, et al: A novel approach to determining violence risk in schizophrenia: developing a stepped strategy in 13,806 discharged patients. PLoS One 7(2):e31727, 2012 22359622
• Singh ML, Papas A: Oral implications of polypharmacy in the elderly. Dent Clin North Am 58(4):783–796, 2014 25201542
• Siskind DJ, Leung J, Russell AW, et al: Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One 11(6):e0156208, 2016a 27304831
• Siskind D, McCartney L, Goldschlager R, Kisely S: Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209(5):385–392, 2016b 27388573
• Siskind DJ, Harris M, Phillipou A, et al: Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci 26(3):325–337, 2017a 27426892
• Siskind D, Siskind V, Kisely S: Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 62(11):772–777, 2017b 28655284
• Siskind DJ, Lee M, Ravindran A, et al: Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry 52(8):751–767, 2018 29732913
• Siskind D, Hahn M, Correll CU, et al: Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab 21(2):293–302, 2019 30187620
• Siu AL; U.S. Preventive Services Task Force: Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 163(8):622–634, 2015 26389730
• Skevington SM, Lotfy M, O’Connell KA; WHOQOL Group: The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL Group. Qual Life Res 13(2):299–310, 2004
• SMI Adviser: How do I establish tolerability before starting a long acting injectable antipsychotic medication (LAI), and how do I ensure the patient will not have side effects? Washington, DC, American Psychiatric Association, September 4, 2019. Available at: https://smiadviser.org/knowledge_post/how-do-i-establishing-tolerability-before-starting-a-long-acting-injectable-antipsychotic-medication-lai-and-how-do-i-ensure-the-patient-will-not-have-side-effects. Accessed October 9, 2019.
• Smith FA, Levenson JL, Stern TA: Psychiatric assessment and consultation, in The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, 3rd Edition. Edited by Levenson JL. Washington, DC, American Psychiatric Association Publishing, 2019, pp 3–24
• Smith PH, Mazure CM, McKee SA: Smoking and mental illness in the U.S. population. Tob Control 23(e2):e147–e153, 2014 24727731
• Soares-Weiser K, Rathbone J: Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev (11):CD000206, 2011 14973950
• Soares-Weiser K, Maayan N, Bergman H: Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Jan 17 1(1):CD000209, 2018a 29341067
• Soares-Weiser K, Rathbone J, Ogawa Y, et al: Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Mar 19 3(3):CD000208, 2018b 29552749
• Solmi M, Pigato G, Kane JM, Correll CU: Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci 389:21–27, 2018a 29439776
• Solmi M, Pigato G, Kane JM, Correll CU: Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 12:1215–1238, 2018b 29795977
• Solmi M, Fornaro M, Toyoshima K, et al: Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectr 24(5):479–495, 2019 30460884
• Sood S, James W, Bailon MJ: Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol 23(1):9–17, 2008 18090503
• Souza JS, Kayo M, Tassell I, et al: Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr 18(2):82–89, 2013 23253621
• Sparshatt A, Taylor D, Patel MX, Kapur S: A systematic review of aripiprazole: dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71(11):1447–1456, 2010 20584524
• Spina E, Sturiale V, Valvo S, et al: Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 8(1):21–24, 1993 8097213
• Spina E, Avenoso A, Facciolà G, et al: Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 148(1):83–89, 2000 10663421
• Spitz A, Studerus E, Koranyi S, et al: Correlations between self-rating and observer-rating of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender. Early Interv Psychiatry 11(6):461–470, 2017 26376725
• Stanilla JK, Simpson GM: Drugs to treat extrapyramidal side effects, in The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5th Edition. Edited by Schatzberg AF, Nemeroff CB. Arlington, VA, American Psychiatric Association Publishing, 2017, pp 855–885
• Stanley B, Brown GK: Safety planning intervention: a brief intervention to mitigate suicide risk. Cognit Behav Pract 19(2):256–264, 2012
• Stanley B, Brown GK: About safety planning. Safety Planning Intervention 2019. Available at: http://suicide safetyplan.com/About_Safety_Planning.html. Accessed December 28, 2018.
• Stanley B, Brown GK, Brenner LA, et al: Comparison of the safety planning intervention with follow-up vs usual care of suicidal patients treated in the emergency department. JAMA Psychiatry 75(9):894–900, 2018 29998307
• Stanton AH, Gunderson JG, Knapp PH, et al: Effects of psychotherapy in schizophrenia I: design and implementation of a controlled study. Schizophr Bull 10(4):520–563, 1984 6151245
• Stark A, Scott J: A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry 46(9):816–825, 2012 22327098
• Steadman HJ, Osher FC, Robbins PC, et al: Prevalence of serious mental illness among jail inmates. Psychiatr Serv 60(6):761–765, 2009 19487344
• Stirman SW, Spokas M, Creed TA, et al: Training and consultation in evidence-based psychosocial treatments in public mental health settings: the ACCESS model. Prof Psychol Res Pr 41(1):48–56, 2010 22872783
• Stoecker ZR, George WT, O’Brien JB, et al: Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol 32(3):155–160, 2017 28059928
• Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 164(6):870–876, 2007 17541044
• Streck JM, Weinberger AH, Pacek LR, et al: Cigarette smoking quit rates among persons with serious psychological distress in the United States from 2008 to 2016: are mental health disparities in cigarette use increasing? Nicotine Tob Res 22(1):130–134, 2020
• Stringhini S, Carmeli C, Jokela M, et al; LIFEPATH consortium: Socioeconomic status and the 25×25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. Lancet 389(10075):1229–1237, 2017 28159391
• Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164(3):415–427, 2007 17329466
• Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators: Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107(1):1–12, 2009 19027269
• Stroup TS, McEvoy JP, Ring KD, et al; Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168(9):947–956, 2011 21768610
• Stroup TS, Byerly MJ, Nasrallah HA, et al: Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 146(1–3):190–195, 2013 23434503
• Stroup TS, Gerhard T, Crystal S, et al: Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 65(2):186–192, 2014 24233347
• Stroup TS, Gerhard T, Crystal S, et al: Comparative effectiveness of adjunctive psychotropic medications in patients with schizophrenia. JAMA Psychiatry 76(5):508–515, 2019
• Strub RL, Black FW: The Mental Status Examination in Neurology. Philadelphia, PA, FA Davis, 2000
• Stubbs B, De Hert M, Sepehry AA, et al: A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 130(6):470–486, 2014 25041606
• Stubbs B, Gaughran F, Mitchell AJ, et al: Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry 37(2):126–133, 2015 25666994
• Stubbs B, Firth J, Berry A, et al: How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophr Res 176(2-3):431–440, 2016a 27261419
• Stubbs B, Vancampfort D, Veronese N, et al: The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: a systematic review and meta-analysis. J Affect Disord 197:259–267, 2016b
• Stübner S, Rustenbeck E, Grohmann R, et al: Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37 (suppl 1):S54–S64, 2004 15052515
• Subotnik KL, Casaus LR, Ventura J, et al: Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry 72(8):822–829, 2015
• Substance Abuse and Mental Health Services Administration: Assertive Community Treatment (ACT) Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, October 2008. Available at: https://store.samhsa.gov/product/Assertive-Community-Treatment-ACT-Evidence-Based-Practices-EBP-KIT/sma08-4345. Accessed March 31, 2019.
• Substance Abuse and Mental Health Services Administration: Family Psychoeducation Evidence-Based Practices (EBP) KIT (HHS Publ No SMA-09-4422). Rockville, MD, Substance Abuse and Mental Health Services Administration, 2009. Available at: https://store.samhsa.gov/product/Family-Psychoeducation-Evidence-Based-Practices-EBP-KIT/sma09-4422. Accessed October 1, 2019.
• Substance Abuse and Mental Health Services Administration: Illness Management and Recovery Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, March 2010a. Available at: https://store.samhsa.gov/product/Illness-Management-and-Recovery-Evidence-Based-Practices-EBP-KIT/sma09-4463. Accessed April 6, 2019.
• Substance Abuse and Mental Health Services Administration: Supported Employment Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, February 2010b. Available at: https://store.samhsa.gov/product/Supported-Employment-Evidence-Based-Practices-EBP-Kit/SMA08-4364. Accessed July 24, 2020.
• Substance Abuse and Mental Health Services Administration: SAMHSA’s working definition of recovery: 10 guiding principles of recovery. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2012a. Available at: https://store.samhsa.gov/system/files/pep12-recdef.pdf. Accessed August 3, 2019.
• Substance Abuse and Mental Health Services Administration: Supported Education Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, August 2012b. Available at: https://store.samhsa.gov/product/Supported-Education-Evidence-Based-Practices-EBP-KIT/SMA11-4654CD-ROM. Accessed August 19, 2019.
• Suijkerbuijk YB, Schaafsma FG, van Mechelen JC, et al: Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis. Cochrane Database Syst Rev Sep 12 9(9):CD011867, 2017 28898402
• Sultana J, Hurtado I, Bejarano-Quisoboni D, et al: Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. Eur J Clin Pharmacol 75(7):1005–1015, 2019 30824947
• Susman VL, Addonizio G: Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 176(4):234–241, 1988 2895164
• Suzuki T, Uchida H, Watanabe K, Kashima H: Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull 44(1):32–60, 2011 22506438
• Swanson CL, Trestman RL: Rural assertive community treatment and telepsychiatry. J Psychiatr Pract 24(4):269–273, 2018 30427810
• Swanson JW, Swartz MS, Van Dorn RA, et al: A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 63(5):490–499, 2006 16651506
• Swanson SJ, Becker DR, Bond GR: Job development guidelines in supported employment. Psychiatr Rehabil J 36(2):122–123, 2013 23750766
• Swartz MS, Wagner HR, Swanson JW, et al: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 194(3):164–172, 2006 16534433
• Swartz MS, Bhattacharya S, Robertson AG, Swanson JW: Involuntary outpatient commitment and the elusive pursuit of violence prevention. Can J Psychiatry 62(2):102–108, 2017 27777274
• Swillen A, McDonald-McGinn D: Developmental trajectories in 22q11.2 deletion. Am J Med Genet C Semin Med Genet 169(2):172–181, 2015 25989227
• Sytema S, Wunderink L, Bloemers W, et al: Assertive community treatment in the Netherlands: a randomized controlled trial. Acta Psychiatr Scand 116(2):105–112, 2007 17650271
• Taipale H, Mehtälä J, Tanskanen A, Tiihonen J: Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia: a nationwide study with 20-year follow-up. Schizophr Bull 44(6):1381–1387, 2018a 29272458
• Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al: Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 197:274–280, 2018b 29274734
• Takeuchi H, Powell V, Geisler S, et al: Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand 134(3):234–240, 2016 27182769
• Takeuchi H, Kantor N, Uchida H, et al: Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull 43(4):862–871, 2017a 28044008
• Takeuchi H, Thiyanavadivel S, Agid O, Remington G: Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: a meta-analysis. Schizophr Res 189:4–8, 2017b 28242107
• Takeuchi H, Siu C, Remington G, et al: Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 44(6):1036–1042, 2019 30514883
• Tam J, Warner KE, Meza R: Smoking and the reduced life expectancy of individuals with serious mental illness. Am J Prev Med 51(6):958–966, 2016 27522471
• Tamburello A, Metzner J, Fergusen E, et al: The American Academy of Psychiatry and the Law practice resource for prescribing in corrections. J Am Acad Psychiatry Law 46(2):242–243, 2018 30026404
• Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H: Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Mar 19 3(3):CD000207, 2018 29553158
• Tang Y, Horvitz-Lennon M, Gellad WF, et al: Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large Medicaid program. Psychiatr Serv 68(6):579–586, 2017 28196460
• Tanskanen A, Tiihonen J, Taipale H: Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatr Scand 138(6):492-499, 2018 29900527
• Tarsy D, Baldessarini RJ: Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21(5):589–598, 2006 16532448
• Tauber R, Wallace CJ, Lecomte T: Enlisting indigenous community supporters in skills training programs for persons with severe mental illness. Psychiatr Serv 51(11):1428–1432, 2000 11058191
• Teasdale SB, Samaras K, Wade T, et al: A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps. J Hum Nutr Diet 30(5):545–553, 2017 28419586
• Thioridazine hydrochloride [prescribing information]. Morgantown, WV, Mylan Pharmaceuticals, November 2016
• Thomas EC, Despeaux KE, Drapalski AL, Bennett M: Person-oriented recovery of individuals with serious mental illnesses: a review and meta-analysis of longitudinal findings. Psychiatr Serv 69(3):259–267, 2018
• Thompson A, Winsper C, Marwaha S, et al: Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych Open 4(4):215–225, 2018 29988997
• Thorning H, Marino L, Jean-Noel P, et al: Adoption of a blended training curriculum for ACT in New York State. Psychiatr Serv 67(9):940–942, 2016 27181739
• Tiihonen J, Haukka J, Taylor M, et al: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603–609, 2011 21362741
• Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al: Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606, 2016 26651392
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al: Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693, 2017 28593216
• Tiihonen J, Tanskanen A, Taipale H: 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 75(8):765–773, 2018 29621900
• Tiihonen J, Taipale H, Mehtälä J, et al: Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76(5):499–507, 2019
• Toftdahl NG, Nordentoft M, Hjorthøj C: Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Soc Psychiatry Psychiatr Epidemiol 51(1):129–140, 2016 26260950
• Toohey MJ, Muralidharan A, Medoff D, et al: Caregiver positive and negative appraisals: effects of the National Alliance on Mental Illness Family-to-Family intervention. J Nerv Ment Dis 204(2):156–159, 2016 26825266
• Tosato S, Albert U, Tomassi S, et al: A systematized review of atypical antipsychotics in pregnant women: balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry 78(5):e477–e489, 2017 28297592
• Trifluoperazine [prescribing information]. Princeton, NJ, Sandoz, October 2017
• Trihexyphenidyl hydrochloride oral solution [prescribing information]. Greenville, SC, Pai Pharmaceutical Associates, October 2010
• Trihexyphenidyl hydrochloride tablets [prescribing information]. Buffalo Grove, IL, Pack Pharmaceuticals, June 2015
• Trotta A, Murray RM, Fisher HL: The impact of childhood adversity on the persistence of psychotic symptoms: a systematic review and meta-analysis. Psychol Med 45(12):2481–2498, 2015 25903153
• Tseng PT, Chen YW, Yeh PY, et al: Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine (Baltimore), 94(47):e1967, 2015 26632691
• Tsuboi T, Bies RR, Suzuki T, et al: Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry 45:178–182, 2013 23727135
• Turkington D, Spencer HM: Back to Life, Back to Normality, Vol 2: CBT Informed Recovery for Families With Relatives With Schizophrenia and Other Psychosis. Cambridge, UK, Cambridge University Press, 2019
• Turkington D, Kingdon D, Weiden PJ: Cognitive behavior therapy for schizophrenia. Am J Psychiatry 163(3):365–373, 2006 16513854
• Turner DT, McGlanaghy E, Cuijpers P, et al: A meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull 44(3):475–491, 2018 29140460
• Twamley EW, Vella L, Burton CZ, et al: Compensatory cognitive training for psychosis: effects in a randomized controlled trial. J Clin Psychiatry 73(9):1212–1219, 2012 22939029
• Uchida H, Suzuki T, Takeuchi H, et al: Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 37(4):788–799, 2011a 19946012
• Uchida H, Takeuchi H, Graff-Guerrero A, et al: Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31(3):318–325, 2011b 21508857
• Unal A, Altindag A, Demir B, Aksoy I: The use of lorazepam and electroconvulsive therapy in the treatment of catatonia: treatment characteristics and outcomes in 60 patients. J ECT 33(4):290–293, 2017 28640169
• Unützer J, Katon W, Callahan CM, et al; IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment: Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 288(22):2836–2845, 2002
• U.S. Department of Health and Human Services: The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA, Centers for Disease Control and Prevention, 2014. Available at: www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm. Accessed December 29, 2018.
• U.S. Department of Health and Human Services; U.S. National Library of Medicine: Chlorpromazine, in LiverTox. U.S. Department of Health and Human Services, October 5, 2017a. Available at: www.ncbi.nlm.nih.gov/books/NBK548793. Accessed May 6, 2020.
• U.S. Department of Health and Human Services; U.S. National Library of Medicine: Antipsychotic agents. Washington, DC, U.S. Department of Health and Human Services, July 20, 2017b. Available at: www.ncbi.nlm.nih.gov/books/NBK548317. Accessed May 6, 2020.
• U.S. Food and Drug Administration: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Silver Spring, MD, U.S. Food and Drug Administration, May 2003. Available at: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm072123.pdf. Accessed May 8, 2019.
• U.S. Food and Drug Administration: FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Silver Spring, MD, U.S. Food and Drug Administration, February 22, 2011a. Available at: www.fda.gov/Drugs/DrugSafety/ucm243903.htm#sa. Accessed September 22, 2019.
• U.S. Food and Drug Administration: Center for Drug Evaluation and Research approval package for Orap (pimozide), NDA 17-473/S046. Silver Spring, MD, U.S. Food and Drug Administration, September 27, 2011b. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2011/017473Orig1s046.pdf. Accessed on February 1, 2019.
• U.S. Food and Drug Administration: FDA approves pill with sensor that digitally tracks if patients have ingested their medication. Silver Spring, MD, U.S. Food and Drug Administration, November 13, 2017. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm. Accessed February 1, 2019.
• U.S. Food and Drug Administration: Table of pharmacogenomic biomarkers in drug labeling. Silver Spring, MD, U.S. Food and Drug Administration, 2019. Available at: www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed August 11, 2019.
• U.S. National Library of Medicine: Daily Med: pimozide tablet. Bethesda, MD, National Institutes of Health, May 2018a. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280. Accessed May 7, 2020.
• U.S. National Library of Medicine: Daily Med. Thioridazine Hydrochloride. Bethesda, MD, National Institutes of Health, December 21, 2018b. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm? setid=52fea941-0b47-41c1-b00d-f88150e8ab93#boxedwarning. Accessed February 8, 2019.
• Üstün TB, Kostanjsek N, Chatterji S, Rehm J: Measuring Health and Disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0). Geneva, Switzerland, World Health Organization, 2010
• Valencia M, Rascon ML, Juarez F, Murow E: A psychosocial skills training approach in Mexican out-patients with schizophrenia. Psychol Med 37(10):1393–1402, 2007 17472761
• Valencia M, Fresan A, Juárez F, et al: The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia. J Psychiatr Res 47(12):1886–1892, 2013 24112947
• Valenstein M, Ganoczy D, McCarthy JF, et al: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 67(10):1542–1550, 2006 17107245
• Valenstein M, Adler DA, Berlant J, et al: Implementing standardized assessments in clinical care: now’s the time. Psychiatr Serv 60(10):1372–1375, 2009
• Valmaggia LR, Tabraham P, Morris E, Bouman TK: Cognitive behavioral therapy across the stages of psychosis: prodromal, first episode, and chronic schizophrenia. Cogn Behav Pract 15(2):179–193, 2008
• Van L, Boot E, Bassett AS: Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. Curr Opin Psychiatry 30(3):191–196, 2017 28230630
• Vancampfort D, Stubbs B, Mitchell AJ, et al: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14(3):339–347, 2015
• Vancampfort D, Correll CU, Galling B, et al: Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 15(2):166–174, 2016a
• Vancampfort D, Rosenbaum S, Schuch FB, et al: Prevalence and predictors of treatment dropout from physical activity interventions in schizophrenia: a meta-analysis. Gen Hosp Psychiatry 39:15–23, 2016b 26719106
• Vancampfort D, Rosenbaum S, Schuch F, et al: Cardiorespiratory fitness in severe mental illness: a systematic review and meta-analysis. Sports Med 47(2):343–352, 2017 27299747
• Vancampfort D, Firth J, Correll CU, et al: The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 18(1):53–66, 2019 30600626
• Van Citters AD, Pratt SI, Jue K, et al: A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness. Community Ment Health J 46(6):540–552, 2010 20012197
• Vandenberk B, Vandael E, Robyns T, et al: Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 5(6):e003264, 2016 27317349
• van der Gaag M, Stant AD, Wolters KJ, et al: Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis. Br J Psychiatry 198(1):59–65, 2011
• Vanderlip ER, Henwood BF, Hrouda DR, et al: Systematic literature review of general health care interventions within programs of assertive community treatment. Psychiatr Serv 68(3):218–224, 2017 27903142
• van der Werf M, Hanssen M, Köhler S, et al: Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia. Psychol Med 44(1):9–16, 2014 23244442
• VanderZwaag C, McGee M, McEvoy JP, et al: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153(12):1579–1584, 1996 8942454
• van Dijk F, de Wit I, Blankers M, et al: The Personal Antipsychotic Choice Index. Pharmacopsychiatry 51(3):89–99, 2018 28810270
• van Duin D, de Winter L, Oud M, et al: The effect of rehabilitation combined with cognitive remediation on functioning in persons with severe mental illness: systematic review and meta-analysis. Psychol Med 49(9):1414–1425, 2019 30696500
• van Dulmen SA, Lukersmith S, Muxlow J, et al; G-I-N Allied Health Steering Group: Supporting a person-centred approach in clinical guidelines: a position paper of the Allied Health Community—Guidelines International Network (G-I-N). Health Expect 18(5):1543–1558, 2015 24118821
• van Harten PN, Hoek HW, Kahn RS: Acute dystonia induced by drug treatment. BMJ 319(7210):623–626, 1999 10473482
• Van Putten T, Aravagiri M, Marder SR, et al: Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull 27(2):91–96, 1991 1924666
• Van Schayck OCP, Williams S, Barchilon V, et al: Treating tobacco dependence: guidance for primary care on life-saving interventions. Position statement of the IPCRG. NPJ Prim Care Respir Med 27(1):38, 2017 28600490
• van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ: Rating scales to measure side effects of antipsychotic medication: a systematic review. J Psychopharmacol 29(8):857–866, 2015 26156860
• Varese F, Smeets F, Drukker M, et al: Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 38(4):661–671, 2012 22461484
• Vaucher J, Keating BJ, Lasserre AM, et al: Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry 23(5):1287–1292, 2018 28115737
• Veerman SR, Schulte PF, Begemann MJ, de Haan L: Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 47(7):231–238, 2014 25121994
• Velligan DI, Lam YW, Glahn DC, et al: Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32(4):724–742, 2006 16707778
• Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness: The Expert Consensus Guideline Series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70 (suppl 4):1–46, 2009 19686636
• Velligan DI, Weiden PJ, Sajatovic M, et al: Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 16(5):306–324, 2010 20859108
• Velligan DI, Medellin E, Draper M, et al: Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J 47(6):654–659, 2011 21253830
• Velligan DI, Sajatovic M, Hatch A, et al: Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 11:449–468, 2017 28424542
• Velthorst E, Koeter M, van der Gaag M, et al: Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med 45(3):453–465, 2015 24993642
• Ventura J, Green MF, Shaner A, Liberman RP: Training and quality assurance in the use of the Brief Psychiatric Rating Scale: the “drift busters.” Int J Methods Psychiatr Res 3:221–244, 1993
• Verbiest M, Brakema E, van der Kleij R, et al: National guidelines for smoking cessation in primary care: a literature review and evidence analysis. NPJ Prim Care Respir Med 27(1):2, 2017 28108747
• Verdoux H, Quiles C, Bachmann CJ, Siskind D: Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res 201:10–19, 2018 29880453
• Verhaeghe N, Clays E, Vereecken C, et al: Health promotion in individuals with mental disorders: a cluster preference randomized controlled trial. BMC Public Health 13:657, 2013 23855449
• Vermeir M, Naessens I, Remmerie B, et al: Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 36(4):769–779, 2008 18227146
• Vermeulen J, van Rooijen G, Doedens P, et al: Antipsychotic medication and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis. Psychol Med 47(13):2217–2228, 2017 28397632
• Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al: Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull 45(2):315–329, 2019 29697804
• Victoroff J, Coburn K, Reeve A, et al: Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci 26(4):283–312, 2014 26037853.
• Viejo LF, Morales V, Puñal P, et al: Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand 107(1):45–49, 2003 12558541
• Viertiö S, Laitinen A, Perälä J, et al: Visual impairment in persons with psychotic disorder. Soc Psychiatry Psychiatr Epidemiol 42(11):902–908, 2007 17846698
• Vinogradov S, Fisher M, Warm H, et al: The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 166(9):1055–1062, 2009 19570929
• Vita A, De Peri L, Barlati S, et al: Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: a prospective study in a real-world setting. Schizophr Res 133(1–3):223–231, 2011 21907544
• Volavka J, Van Dorn RA, Citrome L, et al: Hostility in schizophrenia: an integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. Eur Psychiatry 31:13–19, 2016 26657597
• Vraylar (cariprazine) [prescribing information]. Madison, NJ, Allergan USA, May 2019
• Vuk A, Baretic M, Osvatic MM, et al: Treatment of diabetic ketoacidosis associated with antipsychotic medication: literature review. J Clin Psychopharmacol 37(5):584–589, 2017 28816925
• Waddell L, Taylor M: A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 22(3):238–243, 2008 18541624
• Waddell L, Taylor M: Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 52:S43–S50, 2009 19880916
• Wade M, Tai S, Awenat Y, Haddock G: A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev 51:75–95, 2017 27838461
• Wagner E, Löhrs L, Siskind D, et al: Clozapine augmentation strategies: a systematic meta-review of available evidence: treatment options for clozapine resistance. J Psychopharmacol 33(4):423–435, 2019a
• Wagner E, Wobrock T, Kunze B, et al: Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. Schizophr Res 208:370–376, 2019b
• Walburn J, Gray R, Gournay K, et al: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300–307, 2001 11581109
• Walker ER, McGee RE, Druss BG: Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72(4):334–341, 2015 25671328
• Waln O, Jankovic J: Paroxysmal movement disorders. Neurol Clin 33(1):137–152, 2015 25432727
• Wampold BE: How important are the common factors in psychotherapy? An update. World Psychiatry 14(3):270–277, 2015 26407772
• Wang G, Zheng W, Li XB, et al: ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res 105:23–32, 2018 30144667
• Wang K, Varma DS, Prosperi M: A systematic review of the effectiveness of mobile apps for monitoring and management of mental health symptoms or disorders. J Psychiatr Res 107:73–78, 2018 30347316
• Wang PS, Walker AM, Tsuang MT, et al: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59(12):1147–1154, 2002 12470131
• Ward M, Druss B: The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry 2(5):431–451, 2015 26360287
• Warnez S, Alessi-Severini S: Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 14:102, 2014 24708834
• Watkins K, Horvitz-Lennon M, Caldarone LB, et al: Developing medical record-based performance indicators to measure the quality of mental healthcare. J Healthc Qual 33(1):49–66, quiz 66–67, 2011
• Watkins KE, Farmer CM, De Vries D, Hepner KA: The Affordable Care Act: an opportunity for improving care for substance use disorders? Psychiatr Serv 66(3):310–312, 2015
• Watkins KE, Smith B, Akincigil A, et al: The quality of medication treatment for mental disorders in the Department of Veterans Affairs and in private-sector plans. Psychiatr Serv 67(4):391–396, 2016
• Way BB, Miraglia R, Sawyer DA, Beer RJ: Factors related to suicide in New York State prisons. Int J Law Psychiatry 28(3):207–221, 2005 15950281
• Weaver J, Kawsky J, Corboy A: Antipsychotic use and fracture risk: an evaluation of incidence at a Veterans Affairs medical center. Ment Health Clin 9(1):6–11, 2019 30627497
• Weibell MA, Hegelstad WTV, Auestad B, et al: The effect of substance use on 10-year outcome in first-episode psychosis. Schizophr Bull 43(4):843–851, 2017 28199703
• Weiden PJ, Roma RS, Velligan DI, et al: The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry 76(6):684–690, 2015 25939027
• Wenzlow AT, Ireys HT, Mann B, et al: Effects of a discharge planning program on Medicaid coverage of state prisoners with serious mental illness. Psychiatr Serv 62(1):73–78, 2011 21209303
• West JC, Marcus SC, Wilk J, et al: Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 34(5):995–1001, 2008 18093962
• Whicher CA, Price HC, Holt RIG: Mechanisms in endocrinology: antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol 178(6):R245–R258, 2018 29559497
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92(4):414–417, 2012 22992668
• WHOQOL Group: Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28(3):551–558, 1998
• Wilder CM, Elbogen EB, Moser LL, et al: Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. Psychiatr Serv 61(4):380–385, 2010 20360277
• Wilper AP, Woolhandler S, Boyd JW, et al: The health and health care of US prisoners: results of a nationwide survey. Am J Public Health 99(4):666–672, 2009 19150898
• Wimberley T, MacCabe JH, Laursen TM, et al: Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174(10):990–998, 2017 28750580
• Winston A: Supportive psychotherapy, in The American Psychiatric Publishing Textbook of Psychiatry, 6th Edition. Edited by Hales RE, Yudofsky SC, Roberts LW. Washington, DC, American Psychiatric Publishing, 2014, pp 1161–1186
• Winston A, Rosenthal RN, Pinsker H: Learning Supportive Psychotherapy: An Illustrated Guide. Washington, DC, American Psychiatric Publishing, 2012, p 211
• Witt K, van Dorn R, Fazel S: Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One 8(2):e55942, 2013 23418482
• Witt K, Hawton K, Fazel S: The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset. Schizophr Res 154(1–3):61–67, 2014 24581550
• Witt K, Lichtenstein P, Fazel S: Improving risk assessment in schizophrenia: epidemiological investigation of criminal history factors. Br J Psychiatry 206(5):424–430, 2015
• Wittenauer Welsh J, Janjua AU, Garlow SJ, et al: Use of expert consultation in a complex case of neuroleptic malignant syndrome requiring electroconvulsive therapy. J Psychiatr Pract 22(6):484489, 2016 27824784
• Wium-Andersen MK, Ørsted DD, Nordestgaard BG: Tobacco smoking is causally associated with antipsychotic medication use and schizophrenia, but not with antidepressant medication use or depression. Int J Epidemiol 44(2):566–577, 2015
• Wojcik JD, Falk WE, Fink JS, et al: A review of 32 cases of tardive dystonia. Am J Psychiatry 148(8):1055–1059, 1991 1677236
• Wong J, Delva N: Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 52(7):457–463, 2007 17688010
• Wong Z, Öngür D, Cohen B, et al: Command hallucinations and clinical characteristics of suicidality in patients with psychotic spectrum disorders. Compr Psychiatry 54(6):611–617, 2013 23375263
• Wood L, Burke E, Morrison A: Individual cognitive behavioural therapy for psychosis (CBTp): a systematic review of qualitative literature. Behav Cogn Psychother 43(3):285–297, 2015 24308817
• Woods SW, Morgenstern H, Saksa JR, et al: Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71(4):463–474, 2010 20156410
• Woosley RL, Heise CW, Gallo T: QTdrugs List. Oro Valley, AZ, AZCERT, March 29, 2009. Available at: www.crediblemeds.org. Accessed April 23, 2019.
• Woosley RL, Romero K, Heise CW, et al: Adverse Drug Event Causality Analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death. Drug Saf 40(6):465–474, 2017
• Wright JH, Turkington D, Kingdon DG, Basco MR: Cognitive-Behavior Therapy for Severe Mental Illness: An Illustrated Guide. Washington, DC, American Psychiatric Publishing, 2009
• Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 34(3):523–537, 2008 17962231
• Wykes T, Huddy V, Cellard C, et al: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 168(5):472–485, 2011 21406461
• Xenazine (tetrabenazine) tablets [prescribing information]. Deerfield, IL, Lundbeck, September 2018
• Xia J, Merinder LB, Belgamwar MR: Psychoeducation for schizophrenia (update). Cochrane Database Syst Rev (6):CD002831, 2011 12076455
• Yan H, Chen JD, Zheng XY: Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology (Berl) 229(1):1–7, 2013 23832387
• Yates K, Lång U, Cederlöf M, et al: Association of psychotic experiences with subsequent risk of suicidal ideation, suicide attempts, and suicide deaths: a systematic review and meta-analysis of longitudinal population studies. JAMA Psychiatry 76(2):180–189, 2019
• Yeo V, Dowsey M, Alguera-Lara V, et al: Antipsychotic choice: understanding shared decision-making among doctors and patients. J Ment Health Jun 26:1–8, 2019 31240989 Epub ahead of print
• Yoon HW, Lee JS, Park SJ, et al: Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol 39(6):288–294, 2016 27438182
• Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103–141, 2013 23333322
• Zhang JP, Gallego JA, Robinson DG, et al: Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16(6):1205–1218, 2013 23199972
• Zhang Y, Liu Y, Su Y, et al: The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry 17(1):373, 2017 29162032
• Zheng W, Li XB, Tang YL, et al: Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 35(5):499–509, 2015 26280837
• Zheng W, Cao XL, Ungvari GS, et al: Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS One 11(6):e0156510, 2016 27285996
• Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance, part I. Clin Pharmacokinet 48(11):689–723, 2009 19817501
• Zhu Y, Krause M, Huhn M, et al: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4(9):694–705, 2017 28736102
• Zhuo C, Xu Y, Liu S, et al: Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. Front Pharmacol 9:1393, 2018 30546312
• Zimmer M, Duncan AV, Laitano D, et al: A twelve-week randomized controlled study of the cognitive-behavioral integrated psychological therapy program: positive effect on the social functioning of schizophrenic patients. Braz J Psychiatry 29(2):140–147, 2007 17650536
• Zimmerman M, Chelminski I, Young D, Dalrymple K: Using outcome measures to promote better outcomes. Clinical Neuropsychiatry 8:28–36, 2011
• Zou H, Li Z, Nolan MT, et al: Self-management education interventions for persons with schizophrenia: a meta-analysis. Int J Ment Health Nurs 22(3):256–271, 2013 22882803
• Zubek JP, Bayer L, Shephard JM: Relative effects of prolonged social isolation and confinement: behavioral and EEG changes. J Abnorm Psychol 74(5):625–631, 1969
• Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN, Lilly USA, March 2018a
• Zyprexa (olanzapine) [product monograph]. Toronto, ON, Canada, Eli Lilly Canada, April 2018b
• Zyprexa Relprevv (olanzapine) [prescribing information]. Indianapolis, IN, Eli Lilly, March 2018